

STATISTICAL ANALYSIS PLAN

Final Version 1.1, dated 28-Jan 2020

**A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia
(ELIGANT)**

ISN: 7015-MA-3072

NCT03035032

Astellas Pharma Singapore Pte Ltd

**This confidential document is the property of the sponsor. No unpublished information
contained in this document may be disclosed without prior written approval of the sponsor.**

Table of Contents

I.	LIST OF ABBREVIATIONS AND KEY TERMS	5
1	INTRODUCTION	9
2	FLOW CHART AND VISIT SCHEDULE	9
3	STUDY OBJECTIVE(S) AND DESIGN	10
3.1	Study Objective(s)	10
3.1.1	Primary Objective:	10
3.1.2	Secondary Objectives:	10
3.2	Study Design	10
3.3	Randomization	10
4	CHANGES TO ANALYSIS FROM PROTOCOL	11
5	SAMPLE SIZE	11
6	ANALYSIS SETS	11
6.1	All Subjects Enrolled Set (ENR)	11
6.2	Full Analysis Set (FAS)	11
6.3	Per Protocol Set (PPS)	11
6.3.1	Reasons for Exclusion From PPS	12
6.4	Safety Analysis Set (SAF)	12
6.5	Pharmacokinetics Analysis Set (PKAS)	12
6.6	Pharmacodynamic Analysis Set (PDAS)	12
7	ANALYSIS VARIABLES	12
7.1	Efficacy Endpoints	12
7.1.1	Primary Efficacy Endpoint(s)	12
7.1.2	Secondary Efficacy Endpoints	13
7.1.3	Exploratory Efficacy Endpoints	13
7.1.4	Other Efficacy Variables	13
7.2	Safety Variables	13
7.3	Pharmacokinetic Variables	14
7.4	Pharmacodynamic Variables	14
7.5	Other Variables	14
8	STATISTICAL METHODOLOGY	15
8.1	General Considerations	15

8.2	Study Population	16
8.2.1	Disposition of Subjects	16
8.2.2	Protocol Deviations	16
8.2.3	Demographic and Other Baseline Characteristics	16
8.2.4	Previous and Concomitant Medications	17
8.3	Study Drugs	18
8.3.1	Exposure	18
8.3.2	Treatment Compliance	18
8.4	Analysis of Efficacy	18
8.4.1	Analysis of Primary Endpoint(s)	18
8.4.2	Analysis of Secondary Endpoints	18
8.4.3	Analysis of Exploratory Endpoints	20
8.4.4	Analysis of Other Variables	20
8.5	Analysis of Safety	20
8.5.1	Adverse Events	20
8.5.2	Clinical Laboratory Evaluation	22
8.5.3	Vital Signs	22
8.5.4	ECOG Performance Status	23
8.5.5	Pregnancies	23
8.5.6	Other Safety-Related Observations	23
8.6	Analysis of PK	23
8.7	Analysis of PD	23
8.8	Subgroups of Interest	23
8.9	Other Analyses	23
8.10	Interim Analysis (and Early Discontinuation of the Clinical Study)	23
8.11	Handling of Missing Data, Outliers, Visit Windows, and Other Information	23
8.11.1	Missing Data	23
8.11.2	Outliers	24
8.11.3	Visit Windows	24
8.11.4	Multicenter	24
8.11.5	Retests, Unscheduled Visits and Early Termination Data	24
9	DOCUMENT REVISION HISTORY	25
10	REFERENCES	25
11	APPENDICES	26

11.1	Appendix 1: Key Contributors and Approvers	26
11.2	Appendix 2: Programming Conventions for Outputs	28
11.3	Appendix 3: Algorithm for Treatment Emergence of Adverse Events	29
11.4	Appendix 4: Algorithm for Prior / Concomitant Medications:	30
11.5	Appendix 5: EQ-5D-5L Value Sets	31
11.6	Appendix 6: Lab Reference Ranges	96

I. LIST OF ABBREVIATIONS AND KEY TERMS

List of Abbreviations

Abbreviations	Description of abbreviations
AE	Adverse Event
BMI	Body Mass Index
CI	Confidence Intervals
CRF	Case Report Form
CS	Classification Specifications
CSR	Clinical Study Report
DBP	Diastolic Blood Pressure
DMC	Data Monitoring Committee
FAS	Full Analysis Set
GD	Global Development
H	High
ICH	International Conference on Harmonization
L	Low
LLN	Lower Limit of Normal
LOCF	Last Observation Carried Forward
MedDRA	Medical Dictionary for Regulatory Activities
N	Normal
PD	Pharmacodynamic
PD1-x	Protocol Deviation 1-x
PDAS	Pharmacodynamic Analysis Set
PK	Pharmacokinetic
PKAS	Pharmacokinetics Analysis Set
PPS	Per-Protocol Analysis Set
PT	Preferred Term
SAF	Safety Analysis Set
SAP	Statistical Analysis Plan
SAS	Statistical Analysis Software
SBP	Systolic Blood Pressure
SOC	System Organ Class
TEAE	Treatment Emergent Adverse Event
TLF	Tables, Listings and Figures
ULN	Upper Limit of Normal
WHO-DD	World Health Organization Drug Dictionary

List of Key Terms

Terms	Definition of terms
Adverse Event (AE)	An adverse event is as any untoward medical occurrence in a patient administered a study drug and which does not necessarily have a causal relationship with this treatment (<i>see also Eligard-related AE</i>).
Baseline	1. Observed values/findings which are regarded as starting points for comparison. 2. Time when 'Baseline' is observed.

Case Report Form (CRF)	A printed, optical, or electronic document designed to record all of the protocol required information to be reported to the sponsor for each trial patient.
Castrate Resistant Prostate Cancer (CRPC)	<p>The European Association of Urology (EAU) Prostate Cancer Guidelines 2016 defines CRPC as:</p> <p>Castrate serum testosterone < 50ng/dL or 1.7 nmol/L plus either;</p> <p>Biochemical progression: 3 consecutive rises in prostate specific antigen (PSA) at least 1 week apart resulting in two 50% increases over the nadir, and a PSA > 2 ng/mL or</p> <p>Radiological progression: the appearance of two or more new bone lesions on bone scan or enlargement of a soft tissue lesion using RECIST (Response Evaluation Criteria in Solid Tumors).</p> <p>Symptomatic progression alone must be questioned and is not sufficient to diagnose CRPC.</p>
Causality Assessment	An evaluation performed by a medical professional concerning the likelihood that a therapy or product caused or contributed to an AE. A positive causality assessment made by either reporter and/or company makes an AE into an ADR.
Clinical Study	<p>Any investigation in relation to humans intended:</p> <p>a) to discover or verify the clinical, pharmacological or other pharmacodynamic effects of 1 or more medicinal products;</p> <p>b) to identify any adverse reactions to 1 or more medicinal products; or</p> <p>c) to study the absorption, distribution, metabolism and excretion of 1 or more medicinal products; with the objective of ascertaining their safety or efficacy.</p>
Confidence Interval (CI)	A measure of the precision of an estimated value. The interval represents the range of values, consistent with the data that is believed to encompass the "true" value with high probability (usually 95%) upon repeated sampling according to frequentist theory. The confidence interval (CI) is expressed in the same units as the estimate. Wider intervals indicate lower precision; narrow intervals, greater precision.
Confidentiality	Prevention of disclosure to other than authorized individuals of proprietary information or of a patient's identity.
Consent Form	Document used during the informed consent process that is the basis for explaining to potential patients the risks and potential benefits of a study and the rights and responsibilities of the parties involved. The informed consent document provides a summary of a clinical trial (including its purpose, the treatment procedures and schedule, potential risks and benefits, alternatives to participation, etc.) and explains an individual's rights as a patient. It is designed to begin the informed consent process, which consists of conversations between the patient and the research team.

	If the individual then decides to enter the trial, s/he gives her/his official consent by signing the document. Synonym: informed consent form (ICF)
Contract Research Organization (CRO)	A person or an organization (commercial, academic, or other) contracted by the sponsor to perform 1 or more of a sponsor's trial-related duties and functions.
Data Monitoring	Process by which data are examined for completeness, consistency, and accuracy.
Demographic data	Characteristics of patients or study populations, which include such information as age, sex, family history of the disease or condition for which they are being treated, and other characteristics relevant to the study in which they are participating.
Discontinuation	The act of concluding participation, prior to completion of all protocol-required elements, in a study by an enrolled patient.
Effectiveness	The capability of an intervention in producing a desired result under circumstances that more closely approach real-world practice, with more heterogeneous populations, less-standardized treatment protocols, and delivery in routine clinical settings.
Electronic Case Report Form (eCRF)	Auditable electronic record designed to capture information required by the clinical trial protocol to be reported to the sponsor on each trial patient.
Eligard-related Adverse Event	An adverse event in a patient administered Eligard where a causal relationship is at least a reasonable possibility (drug event with either a possible or probable causal relationship), as determined by the opinion of the investigator. Adverse events listed in the local label should be used by the investigator as reference safety information to understand whether an adverse event is expected with the use of Eligard. This understanding should inform causality assessments by the investigator.
Ethnic Asian	Any of the following races - Chinese, Filipino, Indonesian, Malay, Thai, Vietnamese, Indian, Japanese or Korean.
Final Visit	The final visit will be the same as the last follow-up visit for each patient. It will occur at the 18 th month after enrollment into the study, provided that none of discontinuation criteria (see Section Error! Reference source not found. in protocol) are met.
Protocol	A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the International Conference on Harmonisation – Good Clinical Practice (ICH GCP) Guideline the term protocol refers to protocol and protocol amendments.
Quality of Life (QoL)	A broad ranging concept that incorporates an individual's physical health, psychological state, level of independence, social relationships,


	<p>personal beliefs, and their relationships to salient features of the environment.</p> <p>Note: Quality of Life is one way to measure the benefits or negative impacts of an “improvement” measured in terms of a physiological or psychological symptom. QoL research seeks to quantify what an intervention means to a patient’s sense that their life has changed.</p>
Safety	Relative freedom from harm. In clinical trials, this refers to an absence of harmful side effects resulting from use of the product and may be assessed by laboratory testing of biological samples, special tests and procedures, psychiatric evaluation, and/or physical examination of patients.
Sample Size	A subset of a larger population, selected for investigation to draw conclusions or make estimates about the larger population.
Serious Adverse Event (SAE)	An SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution. An SAE must fulfill at least 1 of the following criteria at any dose level: results in death; is life threatening, results in persistent or significant disability/ incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly, or birth defect; requires inpatient hospitalization or leads to prolongation of hospitalization; or a medically important event.
Serious Eligard-related Adverse Event	<p>An Eligard-related AE which results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, or results in other medically important events.</p> <p>Adverse events listed in the local label should be used by the investigator as reference safety information to understand whether a serious adverse event is expected with the use of Eligard. This understanding should inform causality assessments by the investigator</p>
Statistical Analysis Plan (SAP)	A document that contains a more technical and detailed elaboration of the principal features of the analysis described in the protocol, and includes detailed procedures for executing the statistical analysis of the primary and secondary variables and other data.
Statistical Method	The particular mathematical tests and techniques that are to be used to evaluate the clinical data in a trial.
Study Period	Period of time from the initiation date to the completion date of the study.
Study Population	Defined by protocol inclusion/exclusion criteria.
Visit	A clinical encounter that encompasses planned and unplanned trial interventions, procedures, and assessments that may be performed on a patient. A visit has a start and an end, each described with a rule.
Withdrawal	<p>The act of discontinuing participation in a clinical study.</p> <p><i>See also discontinuation.</i></p>

1 INTRODUCTION

This Statistical Analysis Plan (SAP) contains a more technical and detailed elaboration of the principal features of the analysis described in the protocol, and includes detailed procedures for executing the statistical analysis of the primary and secondary endpoints and other data.

2 FLOW CHART AND VISIT SCHEDULE

Flow Chart



Legend:



Administration of ELIGARD®, details are listed in #.



Data Collection Points

Notes:

#: ELIGARD® will be administered at baseline, 3 months, 6 months, 9 months, 12 months, and 15 months. PSA and Testosterone levels to be measured in all the visits. Visit window is +/- 14 days. QoL to be measured at baseline, 6 months, 12 months and 18 months. Any other assessments including imaging tests are not mandatory and will be performed according to routine standard of care and physician's discretion. One month = 30 days.

Schedule of Assessment

The table of scheduled assessments can be found in Section V of protocol.

3 STUDY OBJECTIVE(S) AND DESIGN

3.1 Study Objective(s)

The objectives of this Phase IV, prospective, interventional study are to evaluate the safety, efficacy, and QoL of ELIGARD® in hormone-dependent prostate cancer patients in Asia.

3.1.1 Primary Objective:

To establish the safety profile of ELIGARD® in ethnic Asian prostate cancer patients.

3.1.2 Secondary Objectives:

- 1) To describe the efficacy of ELIGARD® 22.5 mg (3-monthly formulation) in controlling PSA and testosterone levels
- 2) To assess HRQoL through QoL questionnaires – EORTC QLQ-PR25 and EQ5D-5L

3.2 Study Design

This is a multicenter, prospective, single-arm, interventional study to assess the safety, efficacy, and QoL of ELIGARD® 22.5 mg (3-monthly formulation) in male patients with prostate adenocarcinoma who fulfill the eligibility criteria in Asia. The sample size planned for this study is approximately 107 enrolled prostate cancer patients. The inclusion/exclusion criteria are listed in Section 3.1 and 3.2 in the study protocol. This study will be conducted in approximately 20 centers in 8 countries (Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam).

The enrollment period will be up to 12 months. Patients will be prescreened to confirm access to Androgen Deprivation Therapy (ADT) prior to informed consent. Following written informed consent by the patient and confirmation of eligibility, patients will be treated for 1.5 years (18 months), with ELIGARD® 22.5 mg being administered at baseline, 3rd month, 6th month, 9th month, 12th month and 15th month. AE and SAE collection will start at baseline until the follow-up visit at 18 months (see protocol Section Error! Reference source not found. for AE collection and SAE reporting). QoL will be measured at baseline, 6th month, 12th month and 18th month. The PSA and testosterone levels will be assessed at all scheduled visits and during the follow-up visit. Patients will be followed up at 18th month in the physician's office. The time window for each visit following baseline is +/- 14 days.

A minimum of 1 interim analysis will be conducted when 50 patients complete 1 year of follow-up.

3.3 Randomization

Not Applicable.

4 CHANGES TO ANALYSIS FROM PROTOCOL

1. Patients who are less than 80% compliant with the dosage regimen for any two visit periods during the study should be withdrawn. The two visits are not necessarily consecutive.
2. Added Protocol Deviation rule 5 of windowing convention.
3. Added analyses of PSA reduction in categorical summarization.
4. Included Kaplan-Meier curve for deterioration of quality of life variables (EQ5D02-EQ VAS score, EQ-5D-5L score and QLQ-PR25 score)
5. KM estimates for incidence rate at each scheduled time points will not be provided, as incidence rate is not a time to event variable.

5 SAMPLE SIZE

This study targets to enroll approximately 107 prostate cancer patients meeting all inclusion criteria and none of the exclusion criteria. The sample size calculation is based on assumptions that percentage of ELIGARD®-related AEs will be 50%, a drop-out rate of 10%, and a Wald 95% CI of width 20%, based on a finite population correction, with factor N =10,000 .

6 ANALYSIS SETS

In accordance with International Conference on Harmonization (ICH) recommendations in guidelines E3 and E9, the following analysis sets will be used for the analyses.

6.1 All Subjects Enrolled Set (ENR)

The all subjects enrolled (ENR) set will contain all subjects who provide informed consent for this study. Subject disposition will be presented using ENR.

6.2 Full Analysis Set (FAS)

The full analysis set (FAS) will consist of all patients who are enrolled and receive at least one dose of study drug and have at least one post baseline measurement of PSA and testosterone level.

Specifically, the following will lead to a subject's exclusion from the FAS:

- No study drug taken
- No post baseline measurement of PSA and testosterone.

The FAS will be used for summaries and primary analyses of efficacy data.

6.3 Per Protocol Set (PPS)

The Per-Protocol Set (PPS) includes all subjects of the FAS who do not meet criteria for exclusion from PPS listed in section 6.3.1 of this SAP.

The PPS will be used for secondary analyses of efficacy data. Also, selected demographic and baseline characteristics will be summarized for the PPS.

6.3.1 Reasons for Exclusion From PPS

The following criteria are to capture relevant non-adherence to the protocol and the following reasons may lead to subject's exclusion from PPS:

- Entered into the study even though they did not satisfy entry criteria
- Developed withdrawal criteria during the study and was not withdrawn (Patients who discontinued the study for efficacy-related reasons, such as insufficient therapeutic effect, will be included in the PPS.)
- Full dose was not administered or drug reconstitution was not performed as prescribed
- Patients with treatment compliance <80%
- Patients who used prohibited concomitant medications as defined in the protocol sections 5.1.6 and 12.2.

6.4 Safety Analysis Set (SAF)

The Safety Analysis Set (SAF) consists of all subjects who received at least one ELIGARD® injection and any follow-up safety information is available.

The SAF will be used for statistical summaries of safety data. Demographic and baseline characteristics and all safety and tolerability related variables will be summarized using SAF as well.

6.5 Pharmacokinetics Analysis Set (PKAS)

Not Applicable.

6.6 Pharmacodynamic Analysis Set (PDAS)

Not Applicable.

7 ANALYSIS VARIABLES

The primary endpoint for this study is ELIGARD®-related AEs throughout the entire observation period, as determined by the opinion of the investigator.

Secondary endpoints include:

- Efficacy outcomes of clinical response based on testosterone and PSA levels (Testosterone level and PSA will be assessed for all patients at each scheduled visit, prior to administering ELIGARD®, and at the follow-up visit.)
- HRQoL assessment through QoL questionnaires – EORTC QLQ-PR25 (prostate cancer disease specific PRO) and EQ5D-5L (generic PRO) measured at 0, 6, 12, and 18 months.

7.1 Efficacy Endpoints

7.1.1 Primary Efficacy Endpoint(s)

As the primary analysis of this study is the safety outcomes, primary efficacy variable is not applicable.

7.1.2 Secondary Efficacy Endpoints

The following secondary efficacy endpoints, as derived, are:

- Percentage of patients with Testosterone <20 ng/dL, 20-50ng/dL and >50 ng/dL at 1 and 1.5 years
- Time to PSA progression
- PSA percent reduction to reach $\geq 30\%$, ≥ 50 and $\geq 90\%$
- Scores and change from baseline for EORTC, QLQ-PR25 and EQ-5D-5L

Relevant derivations are as below:

General

Change from baseline = Test value at visit X – baseline value.

Percentage of patients with Testosterone <20 ng/dL, 20-50ng/dL and >50 ng/dL at 1 and 1.5 years

Percentage = (number of patients with corresponding Testosterone level) / (total number of patients in FAS/PPS for that follow-up time).

Time to PSA progression

Time to PSA progression (months) = ((date of 25% or greater increase and an absolute increase of 2ng/mL) - (date of first administration of ELIGARD® 22.5 mg) + 1)/30.

PSA response percentage = number of patients with PSA response (at each visit)/ total number of patients in FAS/PPS.

PSA percent reduction to reach $\geq 30\%$, ≥ 50 and $\geq 90\%$

PSA response percent reduction (%) = ((PSA tested – baseline PSA) / baseline PSA)*100%.

Scores and change from baseline for EORTC, QLQ-PR25 and EQ-5D-5L

For each respective scale, Raw score (RS) = (I1+I2+...+In)/n,

with I_n being the score for each question and n for total number of questions included.

For functional scale (SAC, SFU), Scale score (S) = (1 – (RS-1)/range) * 100, for symptom scales (URI, AID, BOW, HTR), S = ((RS – 1)/range) * 100,

with range defined as the difference between the maximum and minimum possible value of RS, which is 3 for QLQ-PR25.

7.1.3 Exploratory Efficacy Endpoints

Not Applicable.

7.1.4 Other Efficacy Variables

Not Applicable.

7.2 Safety Variables

All outputs for safety outcomes will be based on the Safety Analysis Set. There will be no

statistical comparisons as there is no comparative drug.

Safety will be assessed by evaluation of the following variables:

- Adverse events (AEs), serious adverse events (SAEs), and treatment-emergent adverse events (TEAEs; frequency, severity, seriousness, and relationship to study drug)
- Treatments including any intervention (e.g. medication(s), procedure(s), radiography, surgical treatment, visits to Accident & Emergency department and/or ambulatory clinic, hospitalization) to treat AEs and SAEs
- Clinical laboratory variables (hematology, biochemistry including liver enzymes and total bilirubin, and urinalysis)
- Vital signs (systolic and diastolic blood pressure, respiratory rate and pulse rate)

Treatment emergent adverse events (TEAEs) are defined as AEs with onset dates occurring within the treatment periods, i.e., starts on or after the earliest dosing date of any study treatment and prior to the latest dosing date of any treatment. If the patient early terminates, then AEs happen within early terminate date plus 90 days will be still counted as TEAEs, and after that, AEs occurred will not be seen as TEAEs. TEAEs will be captured and determined on "Adverse Events" page of CRF, with "Onset date of adverse event occurred after first dose of study drug" marked "yes".

For this study, an ELIGARD®-related AE is defined as an adverse event in a patient administered ELIGARD® where a causal relationship is at least a reasonable possibility (drug event with either a possible or probable causal relationship), as determined by the investigator.

Incidence of ELIGARD®-related AE(SAE) is defined as the new ELIGARD®-related AE(SAE) cases happen in study population within the specified period of time. Incidence rate is defined as the number of new cases per population at risk in a given time period.

7.3 Pharmacokinetic Variables

Not Applicable.

7.4 Pharmacodynamic Variables

Not Applicable.

7.5 Other Variables

- The duration of exposure

Duration of exposure months = (date of last study medication administration – date of first study medication administration + 1) / 30.

Duration of exposure years = (date of last study medication administration – date of first study medication administration + 1) / 365.25.

- Cumulative dose

Cumulative dose (mg) = number of injections * 22.5.

Cumulative dose will be calculated in the cases where response to 'drug administered?' and 'reconstituted and mixed as per instructions?' should be 'YES'.

- **Study drug compliance**

Overall compliance to the dosing schedule will be examined for subjects in the safety population.

Compliance with ELIGARD®—based on the injection given or not—will be calculated as the number of injections taken divided by the prescribed number of injections as a percentage, see calculations below.

Compliance for each patient = ((Number of Injections Given provided study drug reconstituted and mixed as per instructions) / Number of Injections Prescribed) * 100%;

While considering number of injections given, study drug must be reconstituted and mixed according to the instructions provided. In case study drug administered but not reconstituted and mixed as per instructions provided, study drug will not be counted in numerator.

- **Duration of Prostate Cancer**

Duration of Prostate Cancer = (Cutoff date of Data – Baseline Assessment Date of Prostate Cancer History+1)/30.

- **Time Since Biopsy**

Time Since Biopsy – (Cutoff Date of Data – Date of Biopsy+1)/30.

Date of biopsy will be taken from prostate cancer history form.

8 STATISTICAL METHODOLOGY

8.1 General Considerations

Unless otherwise specified, baseline is defined as the last non-missing measurement taken prior to reference start date (including unscheduled assessments). In the case where the last non-missing measurement and the reference start date coincide, that measurement will be considered pre-baseline, but Adverse Events (AEs) and medications commencing on the reference start date will be considered post-baseline.

For continuous variables, descriptive statistics will include the number of subjects (n), mean, standard deviation, median, minimum and maximum. When needed, the use of other percentiles (e.g. 25% and 75%) will be mentioned in the relevant section. Frequencies and percentages will be displayed for categorical data. If missing option is not included in summaries, percentages by categories will be based on the number of subjects with missing data, i.e. might not add up to 100%.

Summaries based on FAS and PPS (efficacy data), safety analysis and other summaries based on SAF will be presented by planned region, unless specifically stated otherwise.

No statistical tests will be conducted in this study. Confidence intervals will be 95% for analyses unless specified in the description.

All data processing, summarization, and analyses will be performed using SAS® Version 9.4 or higher on Windows. Sample size is calculated using PASS 14 Power Analysis and Sample

Size Software (2015) version 14.0.2 and validated using nQueries v4.0. Specifications for table, figures, and data listing formats can be found in the TLF specifications for this study.

For the definition of regions, please refer to section 8.11.4.

8.2 Study Population

8.2.1 Disposition of Subjects

All subjects who provide informed consent will be accounted for in this study. ENR will be applied for screened, screen failure, and analysis sets disposition. Summary table will be provided in total, and by region defined in Section 8.11.4.

The following subject data will be presented:

- Number of subjects with informed consent, received study medication and screen failure;
- Number and percentage of subjects allocated to each analysis sets;
- Number and percentage of subjects completed and discontinued the study, and primary reasons for discontinuation and
- Number and percentage of subjects excluded from each analysis sets for each reason defined in Section 5.

8.2.2 Protocol Deviations

Protocol deviations as defined in Section **Error! Reference source not found.** in protocol will be summarized for all patients. Visiting window deviation is added as the 5th protocol deviation. A data listing will be provided by site and patient.

The protocol deviation criteria will be uniquely identified in the summary table and listing. The unique identifiers will be as follows:

- PD1 - Entered into the study even though they did not satisfy entry criteria
- PD2 - Developed withdrawal criteria during the study and was not withdrawn
- PD3 – Full dose was not administered or drug reconstitution was not performed as prescribed
- PD4 - Received excluded concomitant treatment
- PD5 - Window deviation.

8.2.3 Demographic and Other Baseline Characteristics

Demographic data and other baseline characteristics will be presented for the SAF and PPS. Descriptive statistics will include number of patients, mean, SD, median, minimum, maximum, 25th percentile (Q1) and 75th percentile (Q3) for continuous variables, and frequency and percentage for categorical variables. No statistical testing will be carried out for demographic or other baseline characteristics. The following demographic and other baseline characteristics will be reported for this study:

- Age (years) - calculated relative to date of consent
- Sex
- Race
- Country of the investigational site

- Highest education level
- Medical history
- Vital Signs
- Weight(kg)
- Height(cm)
- BMI (kg/m²)
- ECOG performance status
- Laboratory tests

Surgical and Medical History (diabetes, hypertension and cardiac disorders) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) (Version 20.0 or higher). Numbers and percentages of patients will be presented for each System Organ Class (SOC) and Preferred Term (PT) and will be sorted by incidence rate (high to low) and then alphabetic order. The following variables will be summarized to describe the history/status of the disease being studied:

- Prostate cancer history
- Family history for prostate cancer
- Disease characteristics for prostate cancer
- Most important factors for selection of treatment

Disease characteristics include time since diagnosis, Gleason score at initial diagnosis, Tumor, Nodes, Metastasis (TNM) classification, staging, surgical history, biopsy results, dates and types of anti-neoplastic therapy including radiation therapy prior to study inclusion (including number of cycles, treatment duration, time interval since previous treatments), Eastern Cooperative Oncology Group (ECOG) status, bone lesions, soft tissue disease, visceral disease, and pain (using the Visual Analogue Scale [VAS] 0-10).

8.2.4 Previous and Concomitant Medications

Previous medications are medications which started and stopped prior to the first dose of study medication.

Concomitant medications are medications which:

- Started prior to, on or after the first dose of study medication
- AND ended on or after the date of first dose of study medication or were ongoing at the end of the study.

As with previous medication, concomitant medication will be summarized for each regional group using SAF and coded using World Health Organization (WHO) Drug Dictionary Enhanced Version 01Jun2015 or higher. Prior and concomitant medication data will be captured from "Concomitant Medication" page on eCRF. Subjects taking the same medication multiple times will be counted once per medication and investigational period.

Bicalutamide 50 mg O.D. or a similar anti-androgen is an allowed concomitant medication for flare prevention only. Additional administration of an appropriate anti-androgen should be considered beginning three days prior to ELIGARD® treatment and continuing for the first two

to three weeks of treatment to avoid any flare reaction. Use of bicalutamide or similar anti-androgen beyond 3 weeks after starting ELIGARD® therapy and for reasons other than flare prevention is not allowed.

See Appendix 4 for handling of partial dates for medications, in the case where it is not possible to define a medication as prior, or concomitant treatment, the medication will be classified by the worst case; i.e. concomitant.

8.3 Study Drugs

8.3.1 Exposure

Exposure to study medication in months and dose in mg will be presented for the SAF. The dose of each administration is fixed to 22.5mg and can be referenced to “ELIGARD® Use” page from CRF.

The following will be reported:

- Duration of therapy in months, using descriptive statistics
- Number of injections in categorical form and with descriptive statistics
- Cumulative dose with descriptive statistics
- Treatment compliance

The date of first study medication administration will be taken from the eCRF “Date of Visit” form in Baseline folder. The date of last study medication will be taken from the eCRF “End of Treatment” form. In case of missing data, see Appendix 3 for reference to determine the first and last date of study medication. Interruptions and incompliance are not taken into account for duration of exposure.

8.3.2 Treatment Compliance

Overall compliance to study medication will be presented for the SAF. Summary statistics for compliance including mean, SD, median, Q1 and Q3 will be reported. As the study is a fixed-dose injection study, the compliance for each patient through the study is calculated by number of injections divided by total injections administered. Dose injected outside the visit periods will be considered as incompliant. In case dose injected but not reconstituted and mixed as per instructions, it will be considered as incompliant. Patients who are less than 80% compliant with the dosage regimen for any two visit periods (window \pm 14 days) during the study should be withdrawn.

8.4 Analysis of Efficacy

8.4.1 Analysis of Primary Endpoint(s)

Not applicable as the primary endpoint of this study is safety outcomes.

8.4.2 Analysis of Secondary Endpoints

The secondary efficacy analyses will be performed for the FAS and PPS will be used to assess the robustness of the results.

8.4.2.1 Testosterone Level

Testosterone levels are captured on “Serum Testosterone Level” page in CRF. Numbers and percentage of patients with following Testosterone level at 1 and 1.5 years will be summarized:

- <20 ng/dL,
- 20-50 ng/dL,
- >50 ng/dL.

8.4.2.2 PSA Progression and Reduction

PSA progression is defined as a 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value obtained three or more weeks later (captured on “Unscheduled” page in CRF).

Number and percentage of patients to reach following PSA percent reduction will be summarized:

- ≥30%,
- ≥50%,
- ≥90%.

Time to PSA progression (months) = (date of 25% or greater increase and an absolute increase of 2ng/mL) - (date of first administration of ELIGARD® 22.5 mg)/30.

If confirmed by a second value obtained later, the date of first value obtained will be used for calculation.

PSA percent reduction (%) = ((PSA tested– baseline PSA) / baseline PSA)*100%

8.4.2.3 Health-related Quality of Life (HRQoL)

EORTC QLQ-PR25 and EQ-5D-5L (captured on “EORTC QLQ-PR25” and “EQ-5D-5L” page correspondingly in CRF) are used to examine health-related quality of life.

EQ-5D-5L

Number and frequencies for each summary scale, including mobility, self-care, usual activities, pain/discomfort and anxiety/depression will be presented for EQ-5D-5L. Index scores will be generated using Japan, UK and USA value sets (see Appendix 5 for EQ-5D-5L value sets). Absolute index scores, changes from baseline and Kaplan-Meier curves for score deterioration will be presented.

EQ5D02-EQ VAS Score (also captured on “EQ-5D-5L” page) will be presented separately with absolute index score, change from baseline, Kaplan-Meier curves for score deterioration.

EORTC QLQ-PR25

The rule of scoring for QLQ-PR25 follows instruction of EORTC QLQ-PR25 Scoring Manual 2.0. Scale scores after linear transformation (in a 0-100 scale) for each dimension, including urinary symptoms, incontinence aid, bowel symptoms, hormonal treatment related symptoms, sexual activities and sexual function will be presented for QLQ-PR25. Absolute scores of dimensions, changes from baseline and Kaplan-Meier curves for score deterioration will be presented.

8.4.2.4 Tumor Response

Tumors will be evaluated according to the standard of Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Tumor responses are collected and will be summarized for each follow-up visits. FAS and PPS will be used for the analysis of tumor response. Best overall response will also be presented for both datasets.

8.4.3 Analysis of Exploratory Endpoints

Not Applicable.

8.4.4 Analysis of Other Variables

Not Applicable.

8.5 Analysis of Safety

All analysis of safety will be presented by region for SAF, unless specified otherwise.

8.5.1 Adverse Events

7.5.1.1 Adverse events

An Adverse Event (AE) is defined as any untoward medical occurrence in a patient administered a study drug or has undergone study procedures and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. AEs will be captured on CRF page “Adverse Events”, and collected after the first administration of study drug.

Severity is classed using the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Event (CTCAE) guidelines (Version 4.03). The items that are not stipulated in the NCI-CTCAE Version 4.03 will be assessed according to the criteria described in Section 5.6.4 in protocol.

Relationship, as indicated by the Investigator, is classed as “not related”, “possible”, “probable” (increasing severity of relationship). Detailed criteria for causal relationship are listed in Section 5.6.3 in protocol.

All AEs (including TEAEs, ELIGARD®-related AEs) will be coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 20.0 or higher. It will be used to summarize AEs by SOC and PT.

See Appendix 2 for handling of partial dates for AEs. In the case where it is not possible to define an AE as treatment emergent or not, the AE will be classified by the worst case; i.e. ELIGARD®-related / treatment emergent.

An overview table will include the following details:

- Number of AEs, SAEs, TEAEs, and serious TEAEs,
- Number and percentage of subjects with AEs, SAEs, TEAEs, and serious TEAEs,
- Number of ELIGARD®-related AEs, SAEs,

- Number and percentage of subjects with ELIGARD®-related AEs, SAEs,
- Number of TEAEs leading to drug withdrawal and drug interrupted,
- Number and percentage of subjects with TEAEs leading to drug withdrawal and drug interrupted,
- Number of special adverse events and
- Number of death.

7.5.1.2 Adverse events by SOC and/or PT

The number and percentage of subjects with TEAEs, as classified by SOC and PT will be summarized for each region. Summaries will be provided for:

- TEAEs
- drug related TEAEs,
- TEAEs by relationship to study drug,
- TEAEs and drug related TEAEs by severity,
- Drug related AEs and SAEs after CRPC managing,
- TEAEs and drug related TEAEs leading to treatment discontinuation,
- TEAEs and drug related TEAEs leading to drug interruption and,
- TEAEs and drug related TEAEs leading to death

The number of TEAEs and the number and percentage of subjects with TEAEs, as classified by SOC and PT will also be summarized by severity and by relationship to study drug. In the subject count, if a subject has multiple TEAEs with the same SOC or PT, but with differing severity or relationship, then the subject will be counted only once with the worst severity and highest degree of relationship. In the adverse event count, the adverse events will be presented in each category they were classified to. Drug related TEAEs will be presented in a similar way by severity only.

7.5.1.3 Drug Related Adverse Events

The ELIGARD®-related AEs will be summarized according to their severity, NCI CTCAE Grade, outcome, course of event, seriousness, action taken with ELIGARD® and treatment required to manage the AE for SAF set.

The incidence of ELIGARD®-related AEs and SAEs will be analyzed based on SAF. Two-sided 95% symmetric confidence intervals of incidence rates will be calculated based on normal approximation and adjusting for a finite sample size of 10000.

If applicable, estimated median time to first event together with a 95% CI will be prepared. In addition, incidence rates of ELIGARD® -related AEs and SAEs will be summarized at each scheduled visit time-point, together with a 95% CI. AEs that happen on the scheduled visit date will be counted in the visit, and AEs occur after scheduled visit will be counted into next visit.

Time to first occurrence, in months, of ELIGARD® -related AEs and SAEs will be presented graphically using Kaplan-Meier (KM) plots for three regions and all.

8.5.2 Clinical Laboratory Evaluation

The baseline visit is the last measurement taken prior to initial study drug administration.

Quantitative clinical laboratory variables, i.e. hematology, biochemistry, and coagulation will be summarized using mean, standard deviation, minimum, maximum, and median for each region at each visit. Additionally, a within-subject change will be calculated as the post-baseline measurement minus the baseline measurement and summarized in the same way. Each laboratory result will be classified as low (L), normal (N), or high (H) at each visit according to the laboratory supplied reference ranges, if applicable. Values including a comparator will be imputed by rounding 0.01 up or down, i.e., $<x$ will be imputed to $x-0.01$ and $>x$ will be imputed to $x+0.01$.

The number and percentage of subjects within, below and above reference range will be summarized for each region at each visit and last on-treatment.

Frequency tabulations of qualitative clinical laboratory variables (urinalysis and serology) will be presented for each region at each visit.

Laboratory abnormalities will be evaluated on their clinical significance and decided by investigator. Shift tables of change from baseline to each treatment visit, last on-treatment and worst finding during the treatment period will be presented for each region and all.

8.5.3 Vital Signs

The baseline visit is the last measurement taken prior to initial study drug administration. Baseline measurements of systolic and diastolic blood pressure should come from the same measurement and not from different dates.

Vital signs data will be captured on CRF page "Adverse Events" and will be summarized in tables and listings using mean, standard deviation, minimum, maximum, median, Q1 and Q3 by region and visit. The following Vital Signs measurements for both baseline and follow up visits will be reported for this study:

- Systolic Blood Pressure (mmHg)
- Diastolic Blood Pressure (mmHg)
- Respiratory Rate (breaths/min)
- Pulse Rate (bpm)
- Weight (kg)
- Height (m) at baseline only

Additionally, a within-subject change will be calculated per visit as the post-baseline measurement minus the baseline measurement and summarized by region and visit.

Tables for potentially clinically significant vital signs will be presented for SBP, DBP and pulse rate. Summaries will be generated using baseline value and highest value obtained during treatment for each subject for each region.

The following potentially clinically significant criteria are defined for the following parameters:

Vital Sign Variable	Criteria
SBP	≥180 mmHg AND ≥20 mmHg change from baseline
DBP	≥105 mmHg AND ≥15 mmHg change from baseline
Pulse Rate	≥120 bpm AND ≥15 bpm change from baseline

8.5.4 ECOG Performance Status

ECOG performance status data will be captured on CRF page “ECOG Performance Status at Present” and will be summarized by listing number and percentage to relevant analysis set selecting each score scale for each region at each treatment visit and time point, including changes from baseline.

8.5.5 Pregnancies

A detailed listing of all pregnancies will be provided.

8.5.6 Other Safety-Related Observations

Not Applicable.

8.6 Analysis of PK

Not Applicable.

8.7 Analysis of PD

Not Applicable.

8.8 Subgroups of Interest

Not Applicable.

8.9 Other Analyses

Not Applicable.

8.10 Interim Analysis (and Early Discontinuation of the Clinical Study)

A minimum of one interim analysis will be conducted at 20 months when 50 patients will complete 1 year of treatment after the first patient is enrolled. The 20 months timepoint is determined as 50 patients are expected to be recruited at 8 months after the first patient is enrolled. A full analysis will be conducted for interim analysis and will be using this Statistical Analysis Plan. As there are no statistical hypothesis tests in the planned analysis, the conduct of interim analyses will not have any statistical implications on the final study outcome.

8.11 Handling of Missing Data, Outliers, Visit Windows, and Other Information

8.11.1 Missing Data

In general, missing data will not be imputed and the data will be analyzed as they are recorded in the study eCRF. See Appendix 3 for missing value handling of partial dates and treatment - emergent adverse events, and Appendix 4 for determination of prior or concomitant medications. Specifically, missing severity of AEs will be imputed to greatest severity for tabular summarization, and displayed as originally in listings. Missing relationship will be

imputed to “related” for tabular summarization, and displayed as originally in listings. This imputation rule will be applied when summarizing AEs in tables, and missing data will be displayed directly as they are from raw data in listings. For categorical endpoints, the percentage will be calculated based on total number of patients in relevant analysis sets, regardless of whether missing values are present or not. However, if more than 10% of data is missing for one or more key variables, i.e., the safety data, the impact of missing data on the analysis will be discussed, and the pattern of missing data will be explored. If there is evidence of bias in the missing data, and variables that are considered good predictors of the missing data are available, the multiple imputation method at the study level may be used to replace missing values as secondary exploratory analyses. If the multiple imputation method is used, a sensitivity analysis will be carried out comparing results from the complete case analysis (where records with missing data will be dropped) and the full set analysis (with imputed data).

8.11.2 Outliers

All values will be included in the analyses.

8.11.3 Visit Windows

The study protocol gives the overall study schedule and the permissible intervals for these visits as ± 14 days. Subject’s failure to comply with the visit schedule will be regarded as protocol deviation.

8.11.4 Multicenter

This study will be conducted by multiple investigators at 20 centers in 8 countries (Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam).

Data from all centers will be pooled prior to analysis. The analyses will be presented with both pooled data and by region. Hong Kong and Taiwan are considered as greater China region, Indonesia, Malaysia, and Philippines are considered as Asia-Pacific island region, and Singapore, Thailand and Vietnam are considered Indochina Peninsula region. The rule applies to tables, figures and listings.

8.11.5 Retests, Unscheduled Visits and Early Termination Data

In general, for by-visit summaries, data recorded at the scheduled (nominal) visit will be presented. Unscheduled measurements will not be included in by-visit summaries.

In the case of a retest (same visit number assigned), the latest available safety measurement, nearest available efficacy measurement, and lab results closest to that visit will be used for by-visit summaries.

Early termination data will be mapped to the next available visit number for by-visit summaries.

Listings will include scheduled, unscheduled, retest and early discontinuation data.

9 DOCUMENT REVISION HISTORY

<u>Version</u>	<u>Date</u>	<u>Changes</u>	<u>Comment/rationale for change</u>
0.1	24-NOV-2017	NA	Not applicable – 1 st version
0.2	02-APR-2018	1.Updated to Astellas' template; 2.Added deterioration of HRQoL scores; 3.Added PSA reduction analysis; 4. Updated analyses performed for HRQoL; 5. Revised interim analysis time point to 50 patients followed 1 year; 6. Modified sample size calculation.	1, 2, 3, 4 Updated per request from Astellas' team; 5,6 Updated to incorporate protocol amendment 2.0;

10 REFERENCES

7015-MA-3072 ELIGANT Protocol Amendment Version 2.0 Dated 16Jan2018.

7015-MA-3072 ELIGANT Protocol Version 1.0 Dated 30May2016.

Case Report Forms Version 2.0 Dated 29May2017.

EORTC QLQ-PR25 Scoring Manual 2.0

11 APPENDICES

11.1 Appendix 1: Key Contributors and Approvers

List of Key Contributors and Approvers

Key Contributors

The following contributed to or reviewed this Statistical Analysis Plan as relevant to their indicated discipline or role.

Primary author (s)	
PPD	IQVIA
Contributors and Reviewers	
PPD	IQVIA
PPD	IQVIA
PPD	Astellas
PPD	Astellas
PPD	Astellas
PPD	Astellas
PPD	Astellas

Author and Approver Signatories

PPD

IQVIA, was the study statistician for this study.

PPD

, IQVIA was the biostatistics reviewer of this
Statistical Analysis Plan.

This Statistical Analysis Plan was approved by:

PPD

, Astellas Pharma Global Development Inc.

This Statistical Analysis Plan was approved by:

PPD

, Astellas Pharma Singapore Pte Ltd.

11.2 Appendix 2: Programming Conventions for Outputs

Dates & Times

Depending on data available, dates and times will take the form yyyy-mm-ddThh:mm:ss.

Spelling Format

English US.

Presentation of Regions

For outputs, regions will be represented as follows and in that order:

Region	For Tables and Graphs	For Listings (include if different to tables)
Region A: Greater China	Region = Greater China	Same as tables
Region B: Asia-Pacific Islands	Region = Asia-Pacific Islands	Same as tables
Region C: Indochina Peninsula	Region = Indochina Peninsula	Same as tables
Total		

Presentation of Visits

For outputs, visits will be represented as follows and in that order:

Long Name (default)	Short Name
Screening (Visit 0)	Scr (V0)
Baseline (Visit 1)	BL (V1)
3 Month (Visit 2)	M3 (V2)
...	...
18 Month (Visit X)	M18 (Vx)
Early Withdrawal	WD

Listings

A listings will be ordered by the following (unless otherwise indicated in the template):

- center-subject ID,
- date (where applicable)

11.3 Appendix 3: Algorithm for Treatment Emergence of Adverse Events

START DATE	STOP DATE	ACTION
Known	Known	If start date < study med start date, then not TEAE If start date >= study med start date, then TEAE
	Partial	If start date < study med start date, then not TEAE If start date >= study med start date, then TEAE
	Missing	If start date < study med start date, then not TEAE If start date >= study med start date, then TEAE
Partial, but known components show that it cannot be on or after study med start date	Known	Not TEAE
	Partial	Not TEAE
	Missing	Not TEAE
Partial, could be on or after study med start date	Known	If stop date < study med start date, then not TEAE If stop date >= study med start date, then TEAE
	Partial	Impute stop date as latest possible date (i.e. last day of month if day unknown or 31st December if day and month are unknown), then: If stop date < study med start date, then not TEAE If stop date >= study med start date, then TEAE
	Missing	Assumed TEAE
Missing	Known	If stop date < study med start date, then not TEAE If stop date >= study med start date, then TEAE
	Partial	Impute stop date as latest possible date (i.e. last day of month if day unknown or 31st December if day and month are unknown), then: If stop date < study med start date, then not TEAE

START DATE	STOP DATE	ACTION
		If stop date >= study med start date, then TEAE
	Missing	Assumed TEAE

11.4 Appendix 4: Algorithm for Prior / Concomitant Medications:

START DATE	STOP DATE	ACTION
Known	Known	If stop date < study med start date, assign as prior If stop date >= study med start date and start date <= end of treatment, assign as concomitant If stop date >= study med start date and start date > end of treatment, assign as post study
	Partial	Impute stop date as latest possible date (i.e. last day of month if day unknown or 31st December if day and month are unknown), then: If stop date < study med start date, assign as prior If stop date >= study med start date and start date <= end of treatment, assign as concomitant If stop date >= study med start date and start date > end of treatment, assign as post treatment
	Missing	If stop date is missing could never be assumed a prior medication If start date <= end of treatment, assign as concomitant If start date > end of treatment, assign as post treatment
Partial	Known	Impute start date as earliest possible date (i.e. first day of month if day unknown or 1st January if day and month are unknown), then: If stop date < study med start date, assign as prior If stop date >= study med start date and start date <= end of treatment, assign as concomitant If stop date >= study med start date and start date > end of treatment, assign as post treatment

START DATE	STOP DATE	ACTION
	Partial	<p>Impute start date as earliest possible date (i.e. first day of month if day unknown or 1st January if day and month are unknown) and impute stop date as latest possible date (i.e. last day of month if day unknown or 31st December if day and month are unknown), then:</p> <p>If stop date < study med start date, assign as prior</p> <p>If stop date >= study med start date and start date <= end of treatment, assign as concomitant</p> <p>If stop date >= study med start date and start date > end of treatment, assign as post treatment</p>
	Missing	<p>Impute start date as earliest possible date (i.e. first day of month if day unknown or 1st January if day and month are unknown), then:</p> <p>If stop date is missing could never be assumed a prior medication</p> <p>If start date <= end of treatment, assign as concomitant</p> <p>If start date > end of treatment, assign as post treatment</p>
Missing	Known	<p>If stop date < study med start date, assign as prior</p> <p>If stop date >= study med start date, assign as concomitant</p> <p>Cannot be assigned as 'post treatment'</p>
	Partial	<p>Impute stop date as latest possible date (i.e. last day of month if day unknown or 31st December if day and month are unknown), then:</p> <p>If stop date < study med start date, assign as prior</p> <p>If stop date >= study med start date, assign as concomitant</p> <p>Cannot be assigned as 'post treatment'</p>
	Missing	Assign as concomitant

11.5 Appendix 5: EQ-5D-5L Value Sets

5L profile	Japan	UK	US
11111	1.000	1.000	1.000
11112	0.829	0.879	0.876
11113	0.785	0.848	0.844
11114	0.761	0.635	0.700
11115	0.736	0.414	0.550
11121	0.814	0.837	0.861
11122	0.740	0.768	0.820
11123	0.721	0.750	0.809

11124	0.697	0.537	0.669
11125	0.672	0.316	0.524
11131	0.768	0.796	0.827
11132	0.718	0.740	0.806
11133	0.705	0.725	0.800
11134	0.681	0.512	0.661
11135	0.656	0.291	0.517
11141	0.723	0.584	0.682
11142	0.673	0.527	0.663
11143	0.660	0.513	0.659
11144	0.635	0.352	0.544
11145	0.611	0.186	0.426
11151	0.654	0.264	0.463
11152	0.604	0.208	0.450
11153	0.591	0.193	0.446
11154	0.567	0.112	0.369
11155	0.542	0.028	0.289
11211	0.843	0.906	0.888
11212	0.769	0.837	0.846
11213	0.750	0.819	0.835
11214	0.726	0.606	0.695
11215	0.701	0.385	0.550
11221	0.755	0.795	0.832
11222	0.700	0.736	0.796
11223	0.686	0.721	0.786
11224	0.662	0.508	0.654
11225	0.637	0.287	0.517
11231	0.733	0.767	0.818
11232	0.683	0.711	0.783
11233	0.670	0.696	0.774
11234	0.646	0.483	0.644
11235	0.621	0.262	0.508
11241	0.687	0.555	0.676
11242	0.637	0.498	0.647
11243	0.624	0.484	0.640
11244	0.600	0.323	0.532
11245	0.575	0.157	0.421
11251	0.619	0.235	0.463
11252	0.569	0.179	0.443
11253	0.556	0.164	0.437
11254	0.532	0.083	0.365
11255	0.507	-0.001	0.289
11311	0.804	0.883	0.860
11312	0.754	0.827	0.839
11313	0.741	0.812	0.833
11314	0.717	0.599	0.694
11315	0.692	0.378	0.550
11321	0.740	0.785	0.825
11322	0.690	0.728	0.790

11323	0.677	0.714	0.781
11324	0.653	0.501	0.650
11325	0.628	0.280	0.515
11331	0.724	0.760	0.816
11332	0.674	0.704	0.778
11333	0.661	0.689	0.768
11334	0.637	0.476	0.639
11335	0.612	0.255	0.506
11341	0.679	0.548	0.675
11342	0.629	0.491	0.643
11343	0.616	0.477	0.635
11344	0.591	0.316	0.529
11345	0.567	0.150	0.419
11351	0.610	0.228	0.463
11352	0.560	0.172	0.441
11353	0.547	0.157	0.435
11354	0.523	0.076	0.363
11355	0.498	-0.008	0.289
11411	0.775	0.776	0.783
11412	0.725	0.719	0.764
11413	0.712	0.705	0.759
11414	0.688	0.535	0.641
11415	0.663	0.359	0.518
11421	0.711	0.677	0.751
11422	0.661	0.621	0.721
11423	0.648	0.606	0.713
11424	0.624	0.437	0.601
11425	0.599	0.260	0.485
11431	0.695	0.653	0.742
11432	0.645	0.596	0.710
11433	0.632	0.582	0.701
11434	0.608	0.412	0.591
11435	0.583	0.236	0.477
11441	0.649	0.475	0.618
11442	0.599	0.419	0.591
11443	0.586	0.404	0.584
11444	0.562	0.270	0.490
11445	0.537	0.131	0.393
11451	0.581	0.209	0.431
11452	0.531	0.153	0.412
11453	0.518	0.138	0.406
11454	0.494	0.057	0.338
11455	0.469	-0.027	0.266
11511	0.715	0.556	0.626
11512	0.665	0.500	0.613
11513	0.652	0.485	0.609
11514	0.628	0.404	0.532
11515	0.603	0.320	0.452
11521	0.651	0.458	0.599

11522	0.601	0.401	0.579
11523	0.588	0.387	0.574
11524	0.564	0.306	0.501
11525	0.539	0.222	0.425
11531	0.635	0.433	0.592
11532	0.585	0.377	0.571
11533	0.572	0.362	0.565
11534	0.548	0.281	0.493
11535	0.523	0.197	0.418
11541	0.590	0.328	0.501
11542	0.540	0.272	0.483
11543	0.527	0.257	0.478
11544	0.502	0.176	0.410
11545	0.478	0.092	0.339
11551	0.521	0.170	0.365
11552	0.471	0.114	0.352
11553	0.458	0.099	0.348
11554	0.434	0.018	0.285
11555	0.409	-0.066	0.220
12111	0.829	0.846	0.854
12112	0.758	0.779	0.815
12113	0.740	0.761	0.805
12114	0.716	0.548	0.665
12115	0.691	0.327	0.520
12121	0.744	0.737	0.802
12122	0.690	0.678	0.765
12123	0.676	0.663	0.756
12124	0.652	0.450	0.623
12125	0.627	0.229	0.486
12131	0.723	0.709	0.789
12132	0.673	0.653	0.753
12133	0.660	0.638	0.743
12134	0.636	0.425	0.613
12135	0.611	0.204	0.478
12141	0.678	0.497	0.647
12142	0.628	0.441	0.617
12143	0.615	0.426	0.609
12144	0.591	0.266	0.502
12145	0.566	0.099	0.390
12151	0.609	0.177	0.433
12152	0.559	0.121	0.413
12153	0.546	0.106	0.408
12154	0.522	0.025	0.335
12155	0.497	-0.059	0.259
12211	0.773	0.806	0.828
12212	0.719	0.748	0.792
12213	0.705	0.733	0.782
12214	0.681	0.520	0.650
12215	0.656	0.299	0.513

12221	0.705	0.706	0.778
12222	0.654	0.649	0.731
12223	0.641	0.634	0.719
12224	0.617	0.421	0.595
12225	0.592	0.200	0.467
12231	0.688	0.681	0.765
12232	0.638	0.624	0.716
12233	0.625	0.610	0.703
12234	0.601	0.397	0.581
12235	0.576	0.176	0.455
12241	0.642	0.468	0.630
12242	0.592	0.412	0.587
12243	0.579	0.397	0.576
12244	0.555	0.237	0.477
12245	0.530	0.071	0.374
12251	0.574	0.149	0.426
12252	0.524	0.092	0.393
12253	0.511	0.078	0.385
12254	0.487	-0.003	0.320
12255	0.462	-0.088	0.252
12311	0.759	0.796	0.822
12312	0.709	0.740	0.786
12313	0.696	0.725	0.776
12314	0.672	0.512	0.646
12315	0.647	0.291	0.511
12321	0.695	0.698	0.772
12322	0.645	0.642	0.723
12323	0.632	0.627	0.710
12324	0.608	0.414	0.588
12325	0.583	0.193	0.462
12331	0.679	0.673	0.759
12332	0.629	0.617	0.707
12333	0.616	0.602	0.693
12334	0.592	0.389	0.574
12335	0.567	0.168	0.449
12341	0.634	0.461	0.625
12342	0.584	0.405	0.580
12343	0.571	0.390	0.568
12344	0.547	0.230	0.471
12345	0.522	0.063	0.370
12351	0.565	0.141	0.424
12352	0.515	0.085	0.388
12353	0.502	0.070	0.379
12354	0.478	-0.011	0.316
12355	0.453	-0.095	0.250
12411	0.730	0.689	0.748
12412	0.680	0.633	0.717
12413	0.667	0.618	0.709
12414	0.643	0.448	0.597

12415	0.618	0.272	0.482
12421	0.666	0.591	0.703
12422	0.616	0.534	0.659
12423	0.603	0.520	0.648
12424	0.579	0.350	0.545
12425	0.554	0.174	0.438
12431	0.650	0.566	0.692
12432	0.600	0.510	0.645
12433	0.587	0.495	0.632
12434	0.563	0.325	0.531
12435	0.538	0.149	0.427
12441	0.604	0.389	0.573
12442	0.554	0.332	0.533
12443	0.541	0.318	0.522
12444	0.517	0.184	0.437
12445	0.492	0.044	0.348
12451	0.536	0.122	0.395
12452	0.486	0.066	0.364
12453	0.473	0.051	0.356
12454	0.449	-0.030	0.295
12455	0.424	-0.114	0.230
12511	0.670	0.469	0.596
12512	0.620	0.413	0.576
12513	0.607	0.398	0.571
12514	0.583	0.317	0.498
12515	0.558	0.233	0.422
12521	0.606	0.371	0.562
12522	0.556	0.315	0.529
12523	0.543	0.300	0.521
12524	0.519	0.219	0.456
12525	0.494	0.135	0.388
12531	0.590	0.346	0.554
12532	0.540	0.290	0.518
12533	0.527	0.275	0.508
12534	0.503	0.194	0.445
12535	0.478	0.110	0.380
12541	0.545	0.241	0.466
12542	0.495	0.185	0.437
12543	0.482	0.170	0.429
12544	0.458	0.089	0.368
12545	0.433	0.005	0.304
12551	0.476	0.083	0.335
12552	0.426	0.027	0.315
12553	0.413	0.012	0.310
12554	0.389	-0.069	0.251
12555	0.364	-0.153	0.190
13111	0.794	0.815	0.825
13112	0.744	0.759	0.803
13113	0.731	0.744	0.797

13114	0.707	0.531	0.658
13115	0.682	0.310	0.514
13121	0.730	0.717	0.790
13122	0.680	0.660	0.754
13123	0.667	0.646	0.745
13124	0.643	0.433	0.614
13125	0.618	0.212	0.479
13131	0.714	0.692	0.781
13132	0.664	0.636	0.742
13133	0.651	0.621	0.732
13134	0.627	0.408	0.603
13135	0.602	0.187	0.470
13141	0.669	0.480	0.640
13142	0.619	0.423	0.608
13143	0.606	0.409	0.599
13144	0.581	0.248	0.493
13145	0.557	0.082	0.383
13151	0.600	0.160	0.427
13152	0.550	0.104	0.406
13153	0.537	0.089	0.400
13154	0.513	0.008	0.328
13155	0.488	-0.076	0.253
13211	0.759	0.786	0.816
13212	0.709	0.730	0.781
13213	0.696	0.715	0.771
13214	0.672	0.502	0.641
13215	0.647	0.281	0.505
13221	0.695	0.688	0.767
13222	0.645	0.631	0.718
13223	0.632	0.617	0.705
13224	0.608	0.404	0.583
13225	0.583	0.183	0.456
13231	0.679	0.663	0.755
13232	0.629	0.607	0.702
13233	0.616	0.592	0.689
13234	0.592	0.379	0.569
13235	0.567	0.158	0.444
13241	0.633	0.451	0.620
13242	0.583	0.394	0.575
13243	0.570	0.380	0.563
13244	0.546	0.219	0.466
13245	0.521	0.053	0.364
13251	0.565	0.131	0.418
13252	0.515	0.075	0.383
13253	0.502	0.060	0.374
13254	0.478	-0.021	0.311
13255	0.453	-0.105	0.244
13311	0.750	0.779	0.814
13312	0.700	0.723	0.775

13313	0.687	0.708	0.765
13314	0.663	0.495	0.636
13315	0.638	0.274	0.503
13321	0.686	0.681	0.761
13322	0.636	0.624	0.709
13323	0.623	0.610	0.695
13324	0.599	0.397	0.575
13325	0.574	0.176	0.451
13331	0.670	0.656	0.748
13332	0.620	0.600	0.693
13333	0.607	0.585	0.678
13334	0.583	0.372	0.560
13335	0.558	0.151	0.438
13341	0.625	0.444	0.615
13342	0.575	0.387	0.567
13343	0.562	0.373	0.554
13344	0.537	0.212	0.459
13345	0.513	0.046	0.360
13351	0.556	0.124	0.416
13352	0.506	0.068	0.378
13353	0.493	0.053	0.368
13354	0.469	-0.028	0.306
13355	0.444	-0.112	0.242
13411	0.721	0.672	0.740
13412	0.671	0.615	0.707
13413	0.658	0.601	0.699
13414	0.634	0.431	0.589
13415	0.609	0.255	0.474
13421	0.657	0.573	0.693
13422	0.607	0.517	0.647
13423	0.594	0.502	0.635
13424	0.570	0.333	0.533
13425	0.545	0.156	0.428
13431	0.641	0.549	0.682
13432	0.591	0.492	0.632
13433	0.578	0.478	0.619
13434	0.554	0.308	0.519
13435	0.529	0.132	0.416
13441	0.595	0.371	0.564
13442	0.545	0.315	0.521
13443	0.532	0.300	0.510
13444	0.508	0.166	0.426
13445	0.483	0.027	0.339
13451	0.527	0.105	0.387
13452	0.477	0.049	0.355
13453	0.464	0.034	0.346
13454	0.440	-0.047	0.286
13455	0.415	-0.131	0.223
13511	0.661	0.452	0.590

13512	0.611	0.396	0.569
13513	0.598	0.381	0.563
13514	0.574	0.300	0.491
13515	0.549	0.216	0.416
13521	0.597	0.354	0.555
13522	0.547	0.297	0.519
13523	0.534	0.283	0.510
13524	0.510	0.202	0.447
13525	0.485	0.118	0.381
13531	0.581	0.329	0.546
13532	0.531	0.273	0.507
13533	0.518	0.258	0.497
13534	0.494	0.177	0.436
13535	0.469	0.093	0.372
13541	0.536	0.224	0.459
13542	0.486	0.168	0.427
13543	0.473	0.153	0.419
13544	0.448	0.072	0.359
13545	0.424	-0.012	0.297
13551	0.467	0.066	0.329
13552	0.417	0.010	0.308
13553	0.404	-0.005	0.302
13554	0.380	-0.086	0.244
13555	0.355	-0.170	0.184
14111	0.782	0.723	0.753
14112	0.732	0.667	0.733
14113	0.719	0.652	0.728
14114	0.695	0.471	0.604
14115	0.670	0.283	0.475
14121	0.718	0.624	0.720
14122	0.668	0.568	0.688
14123	0.655	0.553	0.680
14124	0.631	0.373	0.563
14125	0.606	0.185	0.442
14131	0.702	0.600	0.712
14132	0.652	0.544	0.677
14133	0.639	0.529	0.668
14134	0.615	0.348	0.553
14135	0.590	0.160	0.434
14141	0.657	0.414	0.583
14142	0.607	0.357	0.554
14143	0.594	0.343	0.546
14144	0.570	0.202	0.450
14145	0.545	0.055	0.349
14151	0.588	0.133	0.388
14152	0.538	0.077	0.369
14153	0.525	0.062	0.364
14154	0.501	-0.019	0.294
14155	0.476	-0.103	0.221

14211	0.747	0.694	0.746
14212	0.697	0.638	0.715
14213	0.684	0.623	0.706
14214	0.660	0.442	0.590
14215	0.635	0.254	0.469
14221	0.683	0.596	0.701
14222	0.633	0.539	0.656
14223	0.620	0.525	0.644
14224	0.596	0.344	0.536
14225	0.571	0.156	0.423
14231	0.667	0.571	0.690
14232	0.617	0.515	0.641
14233	0.604	0.500	0.629
14234	0.580	0.319	0.523
14235	0.555	0.131	0.412
14241	0.622	0.385	0.567
14242	0.572	0.328	0.525
14243	0.559	0.314	0.514
14244	0.535	0.173	0.426
14245	0.510	0.026	0.333
14251	0.553	0.104	0.382
14252	0.503	0.048	0.350
14253	0.490	0.033	0.342
14254	0.466	-0.048	0.280
14255	0.441	-0.132	0.215
14311	0.738	0.687	0.745
14312	0.688	0.631	0.710
14313	0.675	0.616	0.701
14314	0.651	0.435	0.586
14315	0.626	0.247	0.467
14321	0.674	0.588	0.696
14322	0.624	0.532	0.648
14323	0.611	0.517	0.635
14324	0.587	0.337	0.529
14325	0.562	0.149	0.419
14331	0.658	0.564	0.684
14332	0.608	0.508	0.633
14333	0.595	0.493	0.619
14334	0.571	0.312	0.515
14335	0.546	0.124	0.407
14341	0.613	0.378	0.563
14342	0.563	0.321	0.518
14343	0.550	0.307	0.506
14344	0.526	0.166	0.420
14345	0.501	0.019	0.330
14351	0.544	0.097	0.380
14352	0.494	0.041	0.346
14353	0.481	0.026	0.337
14354	0.457	-0.055	0.276

14355	0.432	-0.139	0.213
14411	0.709	0.601	0.681
14412	0.659	0.545	0.651
14413	0.646	0.530	0.644
14414	0.622	0.382	0.544
14415	0.597	0.228	0.440
14421	0.645	0.502	0.638
14422	0.595	0.446	0.595
14423	0.582	0.431	0.584
14424	0.558	0.283	0.492
14425	0.533	0.130	0.397
14431	0.629	0.478	0.627
14432	0.579	0.422	0.581
14433	0.566	0.407	0.569
14434	0.542	0.259	0.479
14435	0.517	0.105	0.386
14441	0.584	0.318	0.517
14442	0.534	0.262	0.478
14443	0.521	0.247	0.468
14444	0.497	0.126	0.390
14445	0.472	0.000	0.310
14451	0.515	0.078	0.353
14452	0.465	0.022	0.324
14453	0.452	0.007	0.316
14454	0.428	-0.074	0.257
14455	0.403	-0.158	0.196
14511	0.649	0.425	0.551
14512	0.599	0.369	0.532
14513	0.586	0.354	0.527
14514	0.562	0.273	0.457
14515	0.537	0.189	0.384
14521	0.585	0.327	0.518
14522	0.535	0.270	0.486
14523	0.522	0.256	0.478
14524	0.498	0.175	0.416
14525	0.473	0.091	0.351
14531	0.569	0.302	0.510
14532	0.519	0.246	0.475
14533	0.506	0.231	0.466
14534	0.482	0.150	0.406
14535	0.457	0.066	0.343
14541	0.524	0.197	0.425
14542	0.474	0.141	0.396
14543	0.461	0.126	0.389
14544	0.437	0.045	0.331
14545	0.412	-0.039	0.270
14551	0.455	0.039	0.297
14552	0.405	-0.017	0.278
14553	0.392	-0.032	0.273

14554	0.368	-0.113	0.217
14555	0.343	-0.197	0.160
15111	0.746	0.436	0.529
15112	0.696	0.380	0.516
15113	0.683	0.365	0.512
15114	0.659	0.284	0.435
15115	0.634	0.200	0.355
15121	0.682	0.338	0.503
15122	0.632	0.281	0.482
15123	0.619	0.267	0.477
15124	0.595	0.186	0.404
15125	0.570	0.102	0.328
15131	0.666	0.313	0.496
15132	0.616	0.257	0.474
15133	0.603	0.242	0.468
15134	0.579	0.161	0.396
15135	0.554	0.077	0.321
15141	0.621	0.208	0.405
15142	0.571	0.152	0.386
15143	0.558	0.137	0.381
15144	0.533	0.056	0.313
15145	0.509	-0.028	0.242
15151	0.552	0.050	0.268
15152	0.502	-0.006	0.255
15153	0.489	-0.021	0.251
15154	0.465	-0.102	0.188
15155	0.440	-0.186	0.123
15211	0.711	0.407	0.529
15212	0.661	0.351	0.509
15213	0.648	0.336	0.503
15214	0.624	0.255	0.430
15215	0.599	0.171	0.354
15221	0.647	0.309	0.496
15222	0.597	0.252	0.463
15223	0.584	0.238	0.454
15224	0.560	0.157	0.389
15225	0.535	0.073	0.321
15231	0.631	0.284	0.487
15232	0.581	0.228	0.452
15233	0.568	0.213	0.442
15234	0.544	0.132	0.379
15235	0.519	0.048	0.312
15241	0.585	0.179	0.400
15242	0.535	0.123	0.370
15243	0.522	0.108	0.362
15244	0.498	0.027	0.301
15245	0.473	-0.057	0.237
15251	0.517	0.021	0.268
15252	0.467	-0.035	0.248

15253	0.454	-0.050	0.242
15254	0.430	-0.131	0.184
15255	0.405	-0.215	0.123
15311	0.702	0.400	0.529
15312	0.652	0.344	0.507
15313	0.639	0.329	0.501
15314	0.615	0.248	0.429
15315	0.590	0.164	0.354
15321	0.638	0.302	0.494
15322	0.588	0.245	0.458
15323	0.575	0.231	0.449
15324	0.551	0.150	0.385
15325	0.526	0.066	0.319
15331	0.622	0.277	0.485
15332	0.572	0.221	0.446
15333	0.559	0.206	0.436
15334	0.535	0.125	0.374
15335	0.510	0.041	0.310
15341	0.577	0.172	0.398
15342	0.527	0.116	0.366
15343	0.514	0.101	0.358
15344	0.489	0.020	0.298
15345	0.465	-0.064	0.235
15351	0.508	0.014	0.268
15352	0.458	-0.042	0.246
15353	0.445	-0.057	0.240
15354	0.421	-0.138	0.183
15355	0.396	-0.222	0.123
15411	0.673	0.381	0.497
15412	0.623	0.325	0.478
15413	0.610	0.310	0.472
15414	0.586	0.229	0.403
15415	0.561	0.145	0.332
15421	0.609	0.282	0.464
15422	0.559	0.226	0.434
15423	0.546	0.211	0.426
15424	0.522	0.130	0.364
15425	0.497	0.046	0.299
15431	0.593	0.258	0.456
15432	0.543	0.202	0.423
15433	0.530	0.187	0.414
15434	0.506	0.106	0.354
15435	0.481	0.022	0.291
15441	0.547	0.153	0.372
15442	0.497	0.097	0.344
15443	0.484	0.082	0.337
15444	0.460	0.001	0.279
15445	0.435	-0.083	0.219
15451	0.479	-0.005	0.245

15452	0.429	-0.061	0.226
15453	0.416	-0.076	0.221
15454	0.392	-0.157	0.167
15455	0.367	-0.241	0.110
15511	0.613	0.342	0.431
15512	0.563	0.286	0.418
15513	0.550	0.271	0.414
15514	0.526	0.190	0.351
15515	0.501	0.106	0.286
15521	0.549	0.244	0.404
15522	0.499	0.187	0.384
15523	0.486	0.173	0.379
15524	0.462	0.092	0.320
15525	0.437	0.008	0.260
15531	0.533	0.219	0.397
15532	0.483	0.163	0.376
15533	0.470	0.148	0.370
15534	0.446	0.067	0.313
15535	0.421	-0.017	0.253
15541	0.488	0.114	0.318
15542	0.438	0.058	0.300
15543	0.425	0.043	0.295
15544	0.400	-0.038	0.241
15545	0.376	-0.122	0.186
15551	0.419	-0.044	0.199
15552	0.369	-0.100	0.186
15553	0.356	-0.115	0.182
15554	0.332	-0.196	0.134
15555	0.307	-0.280	0.084
21111	0.813	0.877	0.880
21112	0.742	0.809	0.840
21113	0.723	0.791	0.830
21114	0.699	0.578	0.690
21115	0.674	0.357	0.544
21121	0.728	0.767	0.826
21122	0.673	0.708	0.790
21123	0.659	0.693	0.780
21124	0.635	0.480	0.648
21125	0.610	0.259	0.511
21131	0.706	0.739	0.813
21132	0.656	0.683	0.777
21133	0.643	0.668	0.768
21134	0.619	0.455	0.638
21135	0.594	0.234	0.502
21141	0.661	0.527	0.671
21142	0.611	0.470	0.641
21143	0.598	0.456	0.634
21144	0.574	0.296	0.526
21145	0.549	0.129	0.415

21151	0.592	0.207	0.457
21152	0.542	0.151	0.437
21153	0.529	0.136	0.432
21154	0.505	0.055	0.359
21155	0.480	-0.029	0.283
21211	0.756	0.836	0.853
21212	0.702	0.778	0.816
21213	0.688	0.762	0.807
21214	0.664	0.549	0.675
21215	0.639	0.328	0.538
21221	0.688	0.735	0.803
21222	0.637	0.679	0.756
21223	0.624	0.664	0.744
21224	0.600	0.451	0.620
21225	0.575	0.230	0.491
21231	0.671	0.710	0.790
21232	0.621	0.654	0.741
21233	0.608	0.639	0.728
21234	0.584	0.426	0.606
21235	0.559	0.205	0.480
21241	0.626	0.498	0.655
21242	0.576	0.442	0.612
21243	0.563	0.427	0.601
21244	0.538	0.267	0.502
21245	0.514	0.100	0.398
21251	0.557	0.178	0.451
21252	0.507	0.122	0.418
21253	0.494	0.107	0.409
21254	0.470	0.026	0.344
21255	0.445	-0.058	0.276
21311	0.742	0.826	0.846
21312	0.692	0.770	0.810
21313	0.679	0.755	0.801
21314	0.655	0.542	0.671
21315	0.630	0.321	0.536
21321	0.678	0.728	0.797
21322	0.628	0.671	0.748
21323	0.615	0.657	0.735
21324	0.591	0.444	0.613
21325	0.566	0.223	0.486
21331	0.662	0.703	0.785
21332	0.612	0.647	0.732
21333	0.599	0.632	0.719
21334	0.575	0.419	0.599
21335	0.550	0.198	0.474
21341	0.617	0.491	0.651
21342	0.567	0.434	0.605
21343	0.554	0.420	0.593
21344	0.530	0.260	0.495

21345	0.505	0.093	0.394
21351	0.548	0.171	0.449
21352	0.498	0.115	0.413
21353	0.485	0.100	0.404
21354	0.461	0.019	0.340
21355	0.436	-0.065	0.274
21411	0.713	0.719	0.772
21412	0.663	0.663	0.741
21413	0.650	0.648	0.733
21414	0.626	0.478	0.622
21415	0.601	0.302	0.507
21421	0.649	0.620	0.728
21422	0.599	0.564	0.684
21423	0.586	0.549	0.673
21424	0.562	0.380	0.569
21425	0.537	0.204	0.462
21431	0.633	0.596	0.717
21432	0.583	0.540	0.670
21433	0.570	0.525	0.658
21434	0.546	0.355	0.556
21435	0.521	0.179	0.451
21441	0.588	0.419	0.598
21442	0.538	0.362	0.558
21443	0.525	0.348	0.547
21444	0.501	0.213	0.462
21445	0.476	0.074	0.373
21451	0.519	0.152	0.420
21452	0.469	0.096	0.389
21453	0.456	0.081	0.381
21454	0.432	0.000	0.319
21455	0.407	-0.084	0.255
21511	0.653	0.499	0.620
21512	0.603	0.443	0.600
21513	0.590	0.428	0.595
21514	0.566	0.347	0.522
21515	0.541	0.263	0.446
21521	0.589	0.401	0.586
21522	0.539	0.344	0.554
21523	0.526	0.330	0.546
21524	0.502	0.249	0.480
21525	0.477	0.165	0.412
21531	0.573	0.376	0.578
21532	0.523	0.320	0.543
21533	0.510	0.305	0.534
21534	0.486	0.224	0.470
21535	0.461	0.140	0.404
21541	0.528	0.271	0.491
21542	0.478	0.215	0.462
21543	0.465	0.200	0.454

21544	0.441	0.119	0.392
21545	0.416	0.035	0.329
21551	0.459	0.113	0.359
21552	0.409	0.057	0.339
21553	0.396	0.042	0.334
21554	0.372	-0.039	0.276
21555	0.347	-0.123	0.215
22111	0.746	0.778	0.823
22112	0.692	0.720	0.786
22113	0.678	0.705	0.777
22114	0.654	0.492	0.645
22115	0.629	0.271	0.507
22121	0.678	0.678	0.772
22122	0.627	0.621	0.725
22123	0.614	0.606	0.713
22124	0.590	0.393	0.589
22125	0.565	0.172	0.461
22131	0.661	0.653	0.760
22132	0.611	0.596	0.710
22133	0.598	0.582	0.697
22134	0.574	0.369	0.575
22135	0.549	0.148	0.449
22141	0.616	0.440	0.624
22142	0.566	0.384	0.581
22143	0.553	0.369	0.570
22144	0.529	0.209	0.471
22145	0.504	0.043	0.368
22151	0.547	0.121	0.420
22152	0.497	0.064	0.387
22153	0.484	0.050	0.379
22154	0.460	-0.031	0.314
22155	0.435	-0.115	0.246
22211	0.707	0.747	0.799
22212	0.656	0.691	0.751
22213	0.643	0.676	0.739
22214	0.619	0.463	0.616
22215	0.594	0.242	0.487
22221	0.642	0.648	0.738
22222	0.592	0.592	0.678
22223	0.579	0.577	0.662
22224	0.555	0.364	0.547
22225	0.530	0.143	0.427
22231	0.626	0.624	0.723
22232	0.576	0.567	0.659
22233	0.563	0.553	0.643
22234	0.539	0.340	0.530
22235	0.514	0.119	0.412
22241	0.581	0.411	0.594
22242	0.531	0.355	0.537

22243	0.518	0.340	0.523
22244	0.494	0.180	0.432
22245	0.469	0.014	0.338
22251	0.512	0.092	0.400
22252	0.462	0.035	0.354
22253	0.449	0.021	0.342
22254	0.425	-0.060	0.285
22255	0.400	-0.144	0.226
22311	0.697	0.740	0.793
22312	0.647	0.683	0.743
22313	0.634	0.669	0.730
22314	0.610	0.456	0.609
22315	0.585	0.235	0.483
22321	0.633	0.641	0.729
22322	0.583	0.585	0.666
22323	0.570	0.570	0.649
22324	0.546	0.357	0.536
22325	0.521	0.136	0.419
22331	0.617	0.617	0.714
22332	0.567	0.560	0.647
22333	0.554	0.546	0.629
22334	0.530	0.333	0.518
22335	0.505	0.112	0.403
22341	0.572	0.404	0.587
22342	0.522	0.348	0.527
22343	0.509	0.333	0.511
22344	0.485	0.173	0.422
22345	0.460	0.007	0.330
22351	0.503	0.085	0.396
22352	0.453	0.028	0.346
22353	0.440	0.014	0.333
22354	0.416	-0.067	0.278
22355	0.391	-0.151	0.221
22411	0.668	0.632	0.724
22412	0.618	0.576	0.680
22413	0.605	0.561	0.668
22414	0.581	0.392	0.565
22415	0.556	0.216	0.459
22421	0.604	0.534	0.666
22422	0.554	0.477	0.608
22423	0.541	0.463	0.593
22424	0.517	0.293	0.498
22425	0.492	0.117	0.400
22431	0.588	0.509	0.652
22432	0.538	0.453	0.590
22433	0.525	0.438	0.574
22434	0.501	0.269	0.482
22435	0.476	0.093	0.386
22441	0.543	0.332	0.540

22442	0.493	0.276	0.485
22443	0.480	0.261	0.471
22444	0.456	0.127	0.394
22445	0.431	-0.013	0.314
22451	0.474	0.066	0.372
22452	0.424	0.009	0.327
22453	0.411	-0.005	0.316
22454	0.387	-0.086	0.262
22455	0.362	-0.170	0.207
22511	0.608	0.413	0.583
22512	0.558	0.356	0.550
22513	0.545	0.342	0.542
22514	0.521	0.261	0.477
22515	0.496	0.177	0.409
22521	0.544	0.314	0.537
22522	0.494	0.258	0.490
22523	0.481	0.243	0.478
22524	0.457	0.162	0.421
22525	0.432	0.078	0.362
22531	0.528	0.290	0.525
22532	0.478	0.233	0.475
22533	0.465	0.219	0.462
22534	0.441	0.138	0.407
22535	0.416	0.054	0.351
22541	0.483	0.185	0.444
22542	0.433	0.128	0.401
22543	0.420	0.114	0.390
22544	0.396	0.033	0.337
22545	0.371	-0.051	0.282
22551	0.414	0.027	0.322
22552	0.364	-0.030	0.289
22553	0.351	-0.044	0.281
22554	0.327	-0.125	0.230
22555	0.302	-0.209	0.178
23111	0.732	0.758	0.811
23112	0.682	0.702	0.775
23113	0.669	0.687	0.766
23114	0.645	0.474	0.635
23115	0.620	0.253	0.500
23121	0.668	0.660	0.761
23122	0.618	0.603	0.712
23123	0.605	0.589	0.699
23124	0.581	0.376	0.577
23125	0.556	0.155	0.451
23131	0.652	0.635	0.749
23132	0.602	0.579	0.696
23133	0.589	0.564	0.683
23134	0.565	0.351	0.563
23135	0.540	0.130	0.439

23141	0.607	0.423	0.615
23142	0.557	0.366	0.569
23143	0.544	0.352	0.557
23144	0.520	0.192	0.460
23145	0.495	0.025	0.359
23151	0.538	0.103	0.413
23152	0.488	0.047	0.377
23153	0.475	0.032	0.368
23154	0.451	-0.049	0.305
23155	0.426	-0.133	0.239
23211	0.697	0.729	0.788
23212	0.647	0.673	0.738
23213	0.634	0.658	0.726
23214	0.610	0.445	0.604
23215	0.585	0.224	0.477
23221	0.633	0.631	0.725
23222	0.583	0.575	0.662
23223	0.570	0.560	0.645
23224	0.546	0.347	0.532
23225	0.521	0.126	0.414
23231	0.617	0.606	0.709
23232	0.567	0.550	0.643
23233	0.554	0.535	0.626
23234	0.530	0.322	0.514
23235	0.505	0.101	0.399
23241	0.572	0.394	0.582
23242	0.522	0.338	0.522
23243	0.509	0.323	0.507
23244	0.484	0.163	0.418
23245	0.460	-0.004	0.326
23251	0.503	0.074	0.390
23252	0.453	0.018	0.341
23253	0.440	0.003	0.328
23254	0.416	-0.078	0.273
23255	0.391	-0.162	0.216
23311	0.688	0.722	0.782
23312	0.638	0.666	0.729
23313	0.625	0.651	0.716
23314	0.601	0.438	0.596
23315	0.576	0.217	0.472
23321	0.624	0.624	0.716
23322	0.574	0.567	0.649
23323	0.561	0.553	0.632
23324	0.537	0.340	0.521
23325	0.512	0.119	0.405
23331	0.608	0.599	0.700
23332	0.558	0.543	0.630
23333	0.545	0.528	0.611
23334	0.521	0.315	0.502

23335	0.496	0.094	0.389
23341	0.563	0.387	0.574
23342	0.513	0.330	0.511
23343	0.500	0.316	0.494
23344	0.476	0.156	0.408
23345	0.451	-0.011	0.318
23351	0.494	0.067	0.385
23352	0.444	0.011	0.332
23353	0.431	-0.004	0.319
23354	0.407	-0.085	0.266
23355	0.382	-0.169	0.211
23411	0.659	0.615	0.714
23412	0.609	0.559	0.667
23413	0.596	0.544	0.655
23414	0.572	0.374	0.554
23415	0.547	0.198	0.449
23421	0.595	0.516	0.654
23422	0.545	0.460	0.593
23423	0.532	0.445	0.577
23424	0.508	0.276	0.484
23425	0.483	0.100	0.388
23431	0.579	0.492	0.639
23432	0.529	0.436	0.574
23433	0.516	0.421	0.558
23434	0.492	0.251	0.467
23435	0.467	0.075	0.373
23441	0.534	0.315	0.528
23442	0.484	0.258	0.471
23443	0.471	0.244	0.456
23444	0.447	0.109	0.381
23445	0.422	-0.030	0.303
23451	0.465	0.048	0.362
23452	0.415	-0.008	0.315
23453	0.402	-0.023	0.303
23454	0.378	-0.104	0.251
23455	0.353	-0.188	0.197
23511	0.599	0.395	0.576
23512	0.549	0.339	0.540
23513	0.536	0.324	0.531
23514	0.512	0.243	0.468
23515	0.487	0.159	0.402
23521	0.535	0.297	0.527
23522	0.485	0.240	0.477
23523	0.472	0.226	0.464
23524	0.448	0.145	0.409
23525	0.423	0.061	0.352
23531	0.519	0.272	0.515
23532	0.469	0.216	0.462
23533	0.456	0.201	0.448

23534	0.432	0.120	0.395
23535	0.407	0.036	0.340
23541	0.474	0.167	0.435
23542	0.424	0.111	0.389
23543	0.411	0.096	0.377
23544	0.387	0.015	0.325
23545	0.362	-0.069	0.272
23551	0.405	0.009	0.315
23552	0.355	-0.047	0.279
23553	0.342	-0.062	0.270
23554	0.318	-0.143	0.221
23555	0.293	-0.227	0.170
24111	0.721	0.666	0.741
24112	0.671	0.610	0.709
24113	0.658	0.595	0.701
24114	0.634	0.414	0.584
24115	0.609	0.227	0.463
24121	0.657	0.568	0.695
24122	0.607	0.511	0.650
24123	0.594	0.497	0.638
24124	0.570	0.316	0.530
24125	0.545	0.128	0.418
24131	0.641	0.543	0.684
24132	0.591	0.487	0.636
24133	0.578	0.472	0.623
24134	0.554	0.291	0.517
24135	0.529	0.104	0.407
24141	0.595	0.357	0.561
24142	0.545	0.300	0.519
24143	0.532	0.286	0.508
24144	0.508	0.145	0.420
24145	0.483	-0.002	0.328
24151	0.527	0.077	0.376
24152	0.477	0.020	0.344
24153	0.464	0.006	0.336
24154	0.440	-0.076	0.274
24155	0.415	-0.160	0.210
24211	0.685	0.637	0.722
24212	0.635	0.581	0.677
24213	0.622	0.566	0.665
24214	0.598	0.385	0.557
24215	0.573	0.198	0.444
24221	0.621	0.539	0.663
24222	0.571	0.482	0.604
24223	0.558	0.468	0.589
24224	0.534	0.287	0.489
24225	0.509	0.099	0.385
24231	0.605	0.514	0.648
24232	0.555	0.458	0.586

24233	0.542	0.443	0.570
24234	0.518	0.262	0.472
24235	0.493	0.075	0.371
24241	0.560	0.328	0.532
24242	0.510	0.272	0.477
24243	0.497	0.257	0.462
24244	0.473	0.116	0.382
24245	0.448	-0.030	0.299
24251	0.491	0.048	0.357
24252	0.441	-0.009	0.312
24253	0.428	-0.023	0.301
24254	0.404	-0.104	0.247
24255	0.379	-0.188	0.191
24311	0.677	0.630	0.717
24312	0.627	0.574	0.669
24313	0.614	0.559	0.656
24314	0.590	0.378	0.550
24315	0.565	0.191	0.440
24321	0.613	0.532	0.655
24322	0.563	0.475	0.593
24323	0.550	0.461	0.577
24324	0.526	0.280	0.479
24325	0.501	0.092	0.377
24331	0.597	0.507	0.640
24332	0.547	0.451	0.574
24333	0.534	0.436	0.557
24334	0.510	0.255	0.461
24335	0.485	0.068	0.362
24341	0.551	0.321	0.525
24342	0.501	0.264	0.466
24343	0.488	0.250	0.451
24344	0.464	0.109	0.373
24345	0.439	-0.038	0.292
24351	0.483	0.041	0.353
24352	0.433	-0.016	0.305
24353	0.420	-0.031	0.292
24354	0.396	-0.112	0.240
24355	0.371	-0.196	0.186
24411	0.647	0.544	0.659
24412	0.597	0.488	0.616
24413	0.584	0.473	0.604
24414	0.560	0.325	0.513
24415	0.535	0.172	0.418
24421	0.583	0.446	0.602
24422	0.533	0.389	0.545
24423	0.520	0.375	0.531
24424	0.496	0.227	0.447
24425	0.471	0.073	0.361
24431	0.567	0.421	0.588

24432	0.517	0.365	0.528
24433	0.504	0.350	0.512
24434	0.480	0.202	0.431
24435	0.455	0.049	0.347
24441	0.522	0.262	0.485
24442	0.472	0.205	0.432
24443	0.459	0.191	0.418
24444	0.435	0.069	0.349
24445	0.410	-0.057	0.277
24451	0.453	0.022	0.331
24452	0.403	-0.035	0.288
24453	0.390	-0.050	0.277
24454	0.366	-0.131	0.226
24455	0.341	-0.215	0.173
24511	0.588	0.369	0.539
24512	0.538	0.312	0.507
24513	0.525	0.298	0.499
24514	0.501	0.217	0.437
24515	0.476	0.133	0.372
24521	0.524	0.270	0.494
24522	0.474	0.214	0.448
24523	0.461	0.199	0.437
24524	0.437	0.118	0.383
24525	0.412	0.034	0.327
24531	0.508	0.246	0.483
24532	0.458	0.189	0.434
24533	0.445	0.175	0.421
24534	0.421	0.094	0.369
24535	0.396	0.010	0.315
24541	0.462	0.140	0.404
24542	0.412	0.084	0.362
24543	0.399	0.069	0.351
24544	0.375	-0.012	0.301
24545	0.350	-0.096	0.248
24551	0.394	-0.018	0.286
24552	0.344	-0.074	0.254
24553	0.331	-0.089	0.245
24554	0.307	-0.170	0.197
24555	0.282	-0.254	0.148
25111	0.684	0.379	0.523
25112	0.634	0.323	0.503
25113	0.621	0.308	0.498
25114	0.597	0.227	0.425
25115	0.572	0.143	0.349
25121	0.620	0.281	0.490
25122	0.570	0.224	0.457
25123	0.557	0.210	0.449
25124	0.533	0.129	0.383
25125	0.508	0.045	0.315

25131	0.604	0.256	0.481
25132	0.554	0.200	0.446
25133	0.541	0.185	0.437
25134	0.517	0.104	0.373
25135	0.492	0.020	0.307
25141	0.559	0.151	0.394
25142	0.509	0.095	0.365
25143	0.496	0.080	0.357
25144	0.472	-0.001	0.295
25145	0.447	-0.085	0.232
25151	0.490	-0.007	0.262
25152	0.440	-0.063	0.242
25153	0.427	-0.078	0.237
25154	0.403	-0.159	0.179
25155	0.378	-0.243	0.118
25211	0.649	0.350	0.517
25212	0.599	0.294	0.484
25213	0.586	0.279	0.475
25214	0.562	0.198	0.410
25215	0.537	0.114	0.342
25221	0.585	0.252	0.470
25222	0.535	0.196	0.424
25223	0.522	0.181	0.412
25224	0.498	0.100	0.355
25225	0.473	0.016	0.296
25231	0.569	0.227	0.459
25232	0.519	0.171	0.409
25233	0.506	0.156	0.397
25234	0.482	0.075	0.342
25235	0.457	-0.009	0.284
25241	0.524	0.122	0.377
25242	0.474	0.066	0.335
25243	0.461	0.051	0.324
25244	0.436	-0.030	0.270
25245	0.412	-0.114	0.215
25251	0.455	-0.036	0.255
25252	0.405	-0.092	0.223
25253	0.392	-0.107	0.214
25254	0.368	-0.188	0.164
25255	0.343	-0.272	0.111
25311	0.640	0.343	0.515
25312	0.590	0.287	0.479
25313	0.577	0.272	0.470
25314	0.553	0.191	0.406
25315	0.528	0.107	0.340
25321	0.576	0.245	0.465
25322	0.526	0.188	0.416
25323	0.513	0.174	0.403
25324	0.489	0.093	0.348

25325	0.464	0.009	0.291
25331	0.560	0.220	0.453
25332	0.510	0.164	0.400
25333	0.497	0.149	0.387
25334	0.473	0.068	0.334
25335	0.448	-0.016	0.279
25341	0.515	0.115	0.373
25342	0.465	0.059	0.328
25343	0.452	0.044	0.316
25344	0.428	-0.037	0.264
25345	0.403	-0.121	0.211
25351	0.446	-0.043	0.253
25352	0.396	-0.099	0.218
25353	0.383	-0.114	0.209
25354	0.359	-0.195	0.160
25355	0.334	-0.279	0.109
25411	0.611	0.324	0.486
25412	0.561	0.268	0.455
25413	0.548	0.253	0.447
25414	0.524	0.172	0.385
25415	0.499	0.088	0.320
25421	0.547	0.226	0.441
25422	0.497	0.169	0.397
25423	0.484	0.155	0.386
25424	0.460	0.074	0.332
25425	0.435	-0.010	0.276
25431	0.531	0.201	0.430
25432	0.481	0.145	0.383
25433	0.468	0.130	0.371
25434	0.444	0.049	0.319
25435	0.419	-0.035	0.265
25441	0.486	0.096	0.352
25442	0.436	0.040	0.311
25443	0.423	0.025	0.301
25444	0.399	-0.056	0.251
25445	0.374	-0.140	0.199
25451	0.417	-0.062	0.234
25452	0.367	-0.118	0.203
25453	0.354	-0.133	0.195
25454	0.330	-0.214	0.148
25455	0.305	-0.298	0.099
25511	0.551	0.285	0.425
25512	0.501	0.229	0.405
25513	0.488	0.214	0.400
25514	0.464	0.133	0.341
25515	0.439	0.049	0.280
25521	0.487	0.187	0.391
25522	0.437	0.130	0.359
25523	0.424	0.116	0.350

25524	0.400	0.035	0.299
25525	0.375	-0.049	0.247
25531	0.471	0.162	0.383
25532	0.421	0.106	0.347
25533	0.408	0.091	0.338
25534	0.384	0.010	0.289
25535	0.359	-0.074	0.238
25541	0.426	0.057	0.308
25542	0.376	0.001	0.278
25543	0.363	-0.014	0.270
25544	0.339	-0.095	0.223
25545	0.314	-0.179	0.174
25551	0.357	-0.101	0.194
25552	0.307	-0.157	0.173
25553	0.294	-0.172	0.168
25554	0.270	-0.253	0.124
25555	0.245	-0.337	0.078
31111	0.773	0.850	0.854
31112	0.723	0.794	0.833
31113	0.710	0.779	0.827
31114	0.686	0.566	0.688
31115	0.661	0.345	0.543
31121	0.709	0.752	0.819
31122	0.659	0.695	0.783
31123	0.646	0.681	0.774
31124	0.622	0.468	0.643
31125	0.597	0.247	0.508
31131	0.693	0.727	0.810
31132	0.643	0.671	0.771
31133	0.630	0.656	0.761
31134	0.606	0.443	0.632
31135	0.581	0.222	0.499
31141	0.648	0.515	0.669
31142	0.598	0.458	0.637
31143	0.585	0.444	0.628
31144	0.560	0.283	0.522
31145	0.536	0.117	0.412
31151	0.579	0.195	0.456
31152	0.529	0.139	0.435
31153	0.516	0.124	0.429
31154	0.492	0.043	0.357
31155	0.467	-0.041	0.282
31211	0.738	0.821	0.845
31212	0.688	0.765	0.810
31213	0.675	0.750	0.801
31214	0.651	0.537	0.670
31215	0.626	0.316	0.535
31221	0.674	0.723	0.796
31222	0.624	0.666	0.748

31223	0.611	0.652	0.735
31224	0.587	0.439	0.613
31225	0.562	0.218	0.486
31231	0.658	0.698	0.784
31232	0.608	0.642	0.732
31233	0.595	0.627	0.719
31234	0.571	0.414	0.598
31235	0.546	0.193	0.473
31241	0.612	0.486	0.650
31242	0.562	0.429	0.604
31243	0.549	0.415	0.593
31244	0.525	0.254	0.495
31245	0.500	0.088	0.393
31251	0.544	0.166	0.448
31252	0.494	0.110	0.413
31253	0.481	0.095	0.403
31254	0.457	0.014	0.340
31255	0.432	-0.070	0.273
31311	0.729	0.814	0.843
31312	0.679	0.758	0.804
31313	0.666	0.743	0.794
31314	0.642	0.530	0.666
31315	0.617	0.309	0.533
31321	0.665	0.716	0.791
31322	0.615	0.659	0.739
31323	0.602	0.645	0.725
31324	0.578	0.432	0.605
31325	0.553	0.211	0.480
31331	0.649	0.691	0.778
31332	0.599	0.635	0.723
31333	0.586	0.620	0.708
31334	0.562	0.407	0.590
31335	0.537	0.186	0.467
31341	0.604	0.479	0.645
31342	0.554	0.422	0.597
31343	0.541	0.408	0.584
31344	0.516	0.247	0.488
31345	0.492	0.081	0.389
31351	0.535	0.159	0.446
31352	0.485	0.103	0.407
31353	0.472	0.088	0.397
31354	0.448	0.007	0.335
31355	0.423	-0.077	0.271
31411	0.700	0.707	0.769
31412	0.650	0.650	0.736
31413	0.637	0.636	0.728
31414	0.613	0.466	0.618
31415	0.588	0.290	0.504
31421	0.636	0.608	0.723

31422	0.586	0.552	0.676
31423	0.573	0.537	0.664
31424	0.549	0.368	0.563
31425	0.524	0.191	0.457
31431	0.620	0.584	0.711
31432	0.570	0.527	0.662
31433	0.557	0.513	0.649
31434	0.533	0.343	0.549
31435	0.508	0.167	0.445
31441	0.574	0.406	0.594
31442	0.524	0.350	0.551
31443	0.511	0.335	0.539
31444	0.487	0.201	0.455
31445	0.462	0.062	0.368
31451	0.506	0.140	0.417
31452	0.456	0.084	0.384
31453	0.443	0.069	0.375
31454	0.419	-0.012	0.315
31455	0.394	-0.096	0.252
31511	0.640	0.487	0.619
31512	0.590	0.431	0.598
31513	0.577	0.416	0.592
31514	0.553	0.335	0.520
31515	0.528	0.251	0.445
31521	0.576	0.389	0.584
31522	0.526	0.332	0.549
31523	0.513	0.318	0.540
31524	0.489	0.237	0.476
31525	0.464	0.153	0.410
31531	0.560	0.364	0.575
31532	0.510	0.308	0.537
31533	0.497	0.293	0.527
31534	0.473	0.212	0.465
31535	0.448	0.128	0.401
31541	0.515	0.259	0.488
31542	0.465	0.203	0.457
31543	0.452	0.188	0.449
31544	0.427	0.107	0.389
31545	0.403	0.023	0.326
31551	0.446	0.101	0.358
31552	0.396	0.045	0.337
31553	0.383	0.030	0.331
31554	0.359	-0.051	0.274
31555	0.334	-0.135	0.214
32111	0.728	0.763	0.816
32112	0.678	0.707	0.780
32113	0.665	0.692	0.770
32114	0.641	0.479	0.640
32115	0.616	0.258	0.505

32121	0.664	0.665	0.766
32122	0.614	0.609	0.716
32123	0.601	0.594	0.704
32124	0.577	0.381	0.582
32125	0.552	0.160	0.455
32131	0.648	0.640	0.753
32132	0.598	0.584	0.701
32133	0.585	0.569	0.687
32134	0.561	0.356	0.567
32135	0.536	0.135	0.443
32141	0.603	0.428	0.619
32142	0.553	0.372	0.573
32143	0.540	0.357	0.561
32144	0.516	0.197	0.464
32145	0.491	0.030	0.364
32151	0.534	0.108	0.418
32152	0.484	0.052	0.382
32153	0.471	0.037	0.372
32154	0.447	-0.044	0.309
32155	0.422	-0.128	0.244
32211	0.693	0.735	0.792
32212	0.643	0.678	0.743
32213	0.630	0.664	0.730
32214	0.606	0.451	0.608
32215	0.581	0.230	0.482
32221	0.629	0.636	0.729
32222	0.579	0.580	0.666
32223	0.566	0.565	0.650
32224	0.542	0.352	0.536
32225	0.517	0.131	0.419
32231	0.613	0.612	0.714
32232	0.563	0.555	0.647
32233	0.550	0.541	0.630
32234	0.526	0.328	0.518
32235	0.501	0.107	0.403
32241	0.567	0.399	0.586
32242	0.517	0.343	0.527
32243	0.504	0.328	0.511
32244	0.480	0.168	0.422
32245	0.455	0.002	0.330
32251	0.499	0.080	0.395
32252	0.449	0.023	0.346
32253	0.436	0.009	0.333
32254	0.412	-0.072	0.278
32255	0.387	-0.157	0.221
32311	0.684	0.727	0.786
32312	0.634	0.671	0.734
32313	0.621	0.656	0.720
32314	0.597	0.443	0.600

32315	0.572	0.222	0.476
32321	0.620	0.629	0.720
32322	0.570	0.573	0.654
32323	0.557	0.558	0.636
32324	0.533	0.345	0.525
32325	0.508	0.124	0.410
32331	0.604	0.604	0.704
32332	0.554	0.548	0.634
32333	0.541	0.533	0.616
32334	0.517	0.320	0.506
32335	0.492	0.099	0.393
32341	0.559	0.392	0.578
32342	0.509	0.336	0.515
32343	0.496	0.321	0.499
32344	0.472	0.161	0.412
32345	0.447	-0.006	0.322
32351	0.490	0.072	0.389
32352	0.440	0.016	0.337
32353	0.427	0.001	0.323
32354	0.403	-0.080	0.270
32355	0.378	-0.164	0.215
32411	0.655	0.620	0.719
32412	0.605	0.564	0.672
32413	0.592	0.549	0.659
32414	0.568	0.379	0.558
32415	0.543	0.203	0.454
32421	0.591	0.522	0.658
32422	0.541	0.465	0.597
32423	0.528	0.451	0.581
32424	0.504	0.281	0.489
32425	0.479	0.105	0.392
32431	0.575	0.497	0.643
32432	0.525	0.441	0.579
32433	0.512	0.426	0.562
32434	0.488	0.256	0.471
32435	0.463	0.080	0.377
32441	0.529	0.320	0.533
32442	0.479	0.263	0.475
32443	0.466	0.249	0.460
32444	0.442	0.115	0.385
32445	0.417	-0.025	0.307
32451	0.461	0.053	0.367
32452	0.411	-0.003	0.319
32453	0.398	-0.018	0.307
32454	0.374	-0.099	0.255
32455	0.349	-0.183	0.202
32511	0.595	0.400	0.581
32512	0.545	0.344	0.545
32513	0.532	0.329	0.535

32514	0.508	0.248	0.472
32515	0.483	0.164	0.407
32521	0.531	0.302	0.531
32522	0.481	0.246	0.482
32523	0.468	0.231	0.469
32524	0.444	0.150	0.414
32525	0.419	0.066	0.357
32531	0.515	0.277	0.519
32532	0.465	0.221	0.466
32533	0.452	0.206	0.452
32534	0.428	0.125	0.399
32535	0.403	0.041	0.344
32541	0.470	0.172	0.440
32542	0.420	0.116	0.393
32543	0.407	0.101	0.381
32544	0.383	0.020	0.330
32545	0.358	-0.064	0.277
32551	0.401	0.014	0.320
32552	0.351	-0.042	0.284
32553	0.338	-0.057	0.274
32554	0.314	-0.138	0.226
32555	0.289	-0.222	0.175
33111	0.719	0.746	0.808
33112	0.669	0.690	0.769
33113	0.656	0.675	0.759
33114	0.632	0.462	0.630
33115	0.607	0.241	0.497
33121	0.655	0.648	0.755
33122	0.605	0.591	0.703
33123	0.592	0.577	0.689
33124	0.568	0.364	0.569
33125	0.543	0.143	0.445
33131	0.639	0.623	0.742
33132	0.589	0.567	0.687
33133	0.576	0.552	0.672
33134	0.552	0.339	0.554
33135	0.527	0.118	0.432
33141	0.594	0.411	0.609
33142	0.544	0.354	0.561
33143	0.531	0.340	0.548
33144	0.506	0.179	0.453
33145	0.482	0.013	0.354
33151	0.525	0.091	0.410
33152	0.475	0.035	0.371
33153	0.462	0.020	0.361
33154	0.438	-0.061	0.300
33155	0.413	-0.145	0.236
33211	0.684	0.717	0.782
33212	0.634	0.661	0.729

33213	0.621	0.646	0.716
33214	0.597	0.433	0.596
33215	0.572	0.212	0.471
33221	0.620	0.619	0.716
33222	0.570	0.562	0.650
33223	0.557	0.548	0.633
33224	0.533	0.335	0.521
33225	0.508	0.114	0.405
33231	0.604	0.594	0.700
33232	0.554	0.538	0.630
33233	0.541	0.523	0.612
33234	0.517	0.310	0.502
33235	0.492	0.089	0.389
33241	0.558	0.382	0.574
33242	0.508	0.325	0.511
33243	0.495	0.311	0.495
33244	0.471	0.150	0.408
33245	0.446	-0.016	0.317
33251	0.490	0.062	0.384
33252	0.440	0.006	0.332
33253	0.427	-0.009	0.319
33254	0.403	-0.090	0.265
33255	0.378	-0.174	0.210
33311	0.675	0.710	0.775
33312	0.625	0.654	0.720
33313	0.612	0.639	0.705
33314	0.588	0.426	0.587
33315	0.563	0.205	0.465
33321	0.611	0.612	0.706
33322	0.561	0.555	0.637
33323	0.548	0.541	0.619
33324	0.524	0.328	0.509
33325	0.499	0.107	0.395
33331	0.595	0.587	0.689
33332	0.545	0.531	0.616
33333	0.532	0.516	0.597
33334	0.508	0.303	0.490
33335	0.483	0.082	0.378
33341	0.550	0.375	0.565
33342	0.500	0.318	0.499
33343	0.487	0.304	0.482
33344	0.462	0.143	0.397
33345	0.438	-0.023	0.309
33351	0.481	0.055	0.378
33352	0.431	-0.001	0.323
33353	0.418	-0.016	0.308
33354	0.394	-0.097	0.257
33355	0.369	-0.181	0.204
33411	0.646	0.603	0.709

33412	0.596	0.546	0.659
33413	0.583	0.532	0.646
33414	0.559	0.362	0.546
33415	0.534	0.186	0.443
33421	0.582	0.504	0.645
33422	0.532	0.448	0.581
33423	0.519	0.433	0.565
33424	0.495	0.264	0.474
33425	0.470	0.087	0.379
33431	0.566	0.480	0.630
33432	0.516	0.423	0.562
33433	0.503	0.409	0.545
33434	0.479	0.239	0.456
33435	0.454	0.063	0.363
33441	0.520	0.302	0.520
33442	0.470	0.246	0.460
33443	0.457	0.231	0.444
33444	0.433	0.097	0.371
33445	0.408	-0.042	0.295
33451	0.452	0.036	0.356
33452	0.402	-0.020	0.306
33453	0.389	-0.035	0.293
33454	0.365	-0.116	0.244
33455	0.340	-0.200	0.192
33511	0.586	0.383	0.573
33512	0.536	0.327	0.534
33513	0.523	0.312	0.524
33514	0.499	0.231	0.463
33515	0.474	0.147	0.399
33521	0.522	0.285	0.521
33522	0.472	0.228	0.468
33523	0.459	0.214	0.454
33524	0.435	0.133	0.401
33525	0.410	0.049	0.346
33531	0.506	0.260	0.508
33532	0.456	0.204	0.452
33533	0.443	0.189	0.437
33534	0.419	0.108	0.386
33535	0.394	0.024	0.333
33541	0.461	0.155	0.430
33542	0.411	0.099	0.380
33543	0.398	0.084	0.368
33544	0.373	0.003	0.318
33545	0.349	-0.081	0.267
33551	0.392	-0.003	0.312
33552	0.342	-0.059	0.273
33553	0.329	-0.074	0.263
33554	0.305	-0.155	0.216
33555	0.280	-0.239	0.167

34111	0.707	0.654	0.739
34112	0.657	0.598	0.704
34113	0.644	0.583	0.695
34114	0.620	0.402	0.580
34115	0.595	0.214	0.461
34121	0.643	0.555	0.690
34122	0.593	0.499	0.642
34123	0.580	0.484	0.629
34124	0.556	0.304	0.523
34125	0.531	0.116	0.413
34131	0.627	0.531	0.678
34132	0.577	0.475	0.627
34133	0.564	0.460	0.613
34134	0.540	0.279	0.509
34135	0.515	0.091	0.401
34141	0.582	0.345	0.556
34142	0.532	0.288	0.512
34143	0.519	0.274	0.500
34144	0.495	0.133	0.413
34145	0.470	-0.014	0.324
34151	0.513	0.064	0.374
34152	0.463	0.008	0.339
34153	0.450	-0.007	0.330
34154	0.426	-0.088	0.270
34155	0.401	-0.172	0.207
34211	0.672	0.625	0.717
34212	0.622	0.569	0.668
34213	0.609	0.554	0.656
34214	0.585	0.373	0.550
34215	0.560	0.185	0.439
34221	0.608	0.527	0.655
34222	0.558	0.470	0.593
34223	0.545	0.456	0.577
34224	0.521	0.275	0.479
34225	0.496	0.087	0.377
34231	0.592	0.502	0.639
34232	0.542	0.446	0.574
34233	0.529	0.431	0.557
34234	0.505	0.250	0.461
34235	0.480	0.062	0.362
34241	0.547	0.316	0.525
34242	0.497	0.259	0.466
34243	0.484	0.245	0.451
34244	0.460	0.104	0.373
34245	0.435	-0.043	0.291
34251	0.478	0.035	0.352
34252	0.428	-0.021	0.304
34253	0.415	-0.036	0.292
34254	0.391	-0.117	0.240

34255	0.366	-0.201	0.186
34311	0.663	0.618	0.711
34312	0.613	0.562	0.660
34313	0.600	0.547	0.646
34314	0.576	0.366	0.542
34315	0.551	0.178	0.434
34321	0.599	0.519	0.646
34322	0.549	0.463	0.581
34323	0.536	0.448	0.564
34324	0.512	0.268	0.468
34325	0.487	0.080	0.369
34331	0.583	0.495	0.630
34332	0.533	0.439	0.561
34333	0.520	0.424	0.543
34334	0.496	0.243	0.450
34335	0.471	0.055	0.352
34341	0.538	0.309	0.517
34342	0.488	0.252	0.455
34343	0.475	0.238	0.439
34344	0.451	0.097	0.363
34345	0.426	-0.050	0.284
34351	0.469	0.028	0.347
34352	0.419	-0.028	0.296
34353	0.406	-0.043	0.282
34354	0.382	-0.124	0.232
34355	0.357	-0.208	0.180
34411	0.634	0.532	0.654
34412	0.584	0.476	0.608
34413	0.571	0.461	0.596
34414	0.547	0.313	0.506
34415	0.522	0.159	0.413
34421	0.570	0.433	0.594
34422	0.520	0.377	0.535
34423	0.507	0.362	0.519
34424	0.483	0.214	0.438
34425	0.458	0.061	0.353
34431	0.554	0.409	0.580
34432	0.504	0.353	0.516
34433	0.491	0.338	0.500
34434	0.467	0.190	0.421
34435	0.442	0.036	0.338
34441	0.509	0.249	0.478
34442	0.459	0.193	0.422
34443	0.446	0.178	0.407
34444	0.422	0.057	0.340
34445	0.397	-0.069	0.270
34451	0.440	0.009	0.326
34452	0.390	-0.047	0.280
34453	0.377	-0.062	0.268

34454	0.353	-0.143	0.219
34455	0.328	-0.227	0.169
34511	0.574	0.356	0.537
34512	0.524	0.300	0.502
34513	0.511	0.285	0.493
34514	0.487	0.204	0.433
34515	0.462	0.120	0.370
34521	0.510	0.258	0.489
34522	0.460	0.201	0.440
34523	0.447	0.187	0.428
34524	0.423	0.106	0.375
34525	0.398	0.022	0.321
34531	0.494	0.233	0.477
34532	0.444	0.177	0.425
34533	0.431	0.162	0.411
34534	0.407	0.081	0.361
34535	0.382	-0.003	0.309
34541	0.449	0.128	0.400
34542	0.399	0.072	0.354
34543	0.386	0.057	0.343
34544	0.362	-0.024	0.294
34545	0.337	-0.108	0.244
34551	0.380	-0.030	0.283
34552	0.330	-0.086	0.248
34553	0.317	-0.101	0.239
34554	0.293	-0.182	0.193
34555	0.268	-0.266	0.145
35111	0.671	0.367	0.522
35112	0.621	0.311	0.501
35113	0.608	0.296	0.495
35114	0.584	0.215	0.423
35115	0.559	0.131	0.348
35121	0.607	0.269	0.487
35122	0.557	0.212	0.452
35123	0.544	0.198	0.443
35124	0.520	0.117	0.379
35125	0.495	0.033	0.313
35131	0.591	0.244	0.478
35132	0.541	0.188	0.440
35133	0.528	0.173	0.430
35134	0.504	0.092	0.368
35135	0.479	0.008	0.304
35141	0.546	0.139	0.391
35142	0.496	0.083	0.360
35143	0.483	0.068	0.352
35144	0.458	-0.013	0.292
35145	0.434	-0.097	0.229
35151	0.477	-0.019	0.261
35152	0.427	-0.075	0.240

35153	0.414	-0.090	0.234
35154	0.390	-0.171	0.177
35155	0.365	-0.255	0.117
35211	0.636	0.338	0.514
35212	0.586	0.282	0.479
35213	0.573	0.267	0.469
35214	0.549	0.186	0.406
35215	0.524	0.102	0.339
35221	0.572	0.240	0.465
35222	0.522	0.183	0.416
35223	0.509	0.169	0.403
35224	0.485	0.088	0.348
35225	0.460	0.004	0.290
35231	0.556	0.215	0.452
35232	0.506	0.159	0.400
35233	0.493	0.144	0.387
35234	0.469	0.063	0.334
35235	0.444	-0.021	0.278
35241	0.510	0.110	0.372
35242	0.460	0.054	0.327
35243	0.447	0.039	0.315
35244	0.423	-0.042	0.264
35245	0.398	-0.126	0.210
35251	0.442	-0.048	0.252
35252	0.392	-0.104	0.217
35253	0.379	-0.119	0.208
35254	0.355	-0.200	0.159
35255	0.330	-0.284	0.108
35311	0.627	0.331	0.512
35312	0.577	0.275	0.473
35313	0.564	0.260	0.463
35314	0.540	0.179	0.401
35315	0.515	0.095	0.337
35321	0.563	0.233	0.459
35322	0.513	0.176	0.407
35323	0.500	0.162	0.393
35324	0.476	0.081	0.340
35325	0.451	-0.004	0.285
35331	0.547	0.208	0.446
35332	0.497	0.152	0.391
35333	0.484	0.137	0.376
35334	0.460	0.056	0.325
35335	0.435	-0.028	0.272
35341	0.502	0.103	0.368
35342	0.452	0.047	0.319
35343	0.439	0.032	0.307
35344	0.414	-0.049	0.257
35345	0.390	-0.133	0.206
35351	0.433	-0.055	0.250

35352	0.383	-0.111	0.212
35353	0.370	-0.126	0.202
35354	0.346	-0.207	0.155
35355	0.321	-0.291	0.106
35411	0.598	0.312	0.483
35412	0.548	0.256	0.450
35413	0.535	0.241	0.441
35414	0.511	0.160	0.381
35415	0.486	0.076	0.318
35421	0.534	0.213	0.436
35422	0.484	0.157	0.389
35423	0.471	0.142	0.377
35424	0.447	0.061	0.325
35425	0.422	-0.023	0.271
35431	0.518	0.189	0.424
35432	0.468	0.133	0.374
35433	0.455	0.118	0.361
35434	0.431	0.037	0.312
35435	0.406	-0.047	0.260
35441	0.472	0.084	0.347
35442	0.422	0.028	0.304
35443	0.409	0.013	0.293
35444	0.385	-0.068	0.245
35445	0.360	-0.152	0.195
35451	0.404	-0.074	0.231
35452	0.354	-0.130	0.198
35453	0.341	-0.145	0.190
35454	0.317	-0.226	0.144
35455	0.292	-0.310	0.097
35511	0.538	0.273	0.424
35512	0.488	0.217	0.403
35513	0.475	0.202	0.397
35514	0.451	0.121	0.339
35515	0.426	0.037	0.279
35521	0.474	0.175	0.389
35522	0.424	0.118	0.353
35523	0.411	0.104	0.344
35524	0.387	0.023	0.295
35525	0.362	-0.062	0.244
35531	0.458	0.150	0.380
35532	0.408	0.094	0.341
35533	0.395	0.079	0.331
35534	0.371	-0.002	0.284
35535	0.346	-0.086	0.235
35541	0.413	0.045	0.305
35542	0.363	-0.011	0.273
35543	0.350	-0.026	0.265
35544	0.325	-0.107	0.219
35545	0.301	-0.191	0.172

35551	0.344	-0.113	0.193
35552	0.294	-0.169	0.171
35553	0.281	-0.184	0.165
35554	0.257	-0.265	0.122
35555	0.232	-0.349	0.077
41111	0.748	0.813	0.824
41112	0.698	0.757	0.804
41113	0.685	0.742	0.798
41114	0.661	0.539	0.663
41115	0.636	0.327	0.523
41121	0.684	0.714	0.790
41122	0.634	0.658	0.755
41123	0.621	0.643	0.747
41124	0.597	0.440	0.620
41125	0.572	0.229	0.489
41131	0.668	0.690	0.781
41132	0.618	0.634	0.744
41133	0.605	0.619	0.734
41134	0.581	0.416	0.609
41135	0.556	0.204	0.480
41141	0.623	0.485	0.643
41142	0.573	0.429	0.612
41143	0.560	0.414	0.604
41144	0.536	0.260	0.501
41145	0.511	0.099	0.394
41151	0.554	0.177	0.436
41152	0.504	0.121	0.415
41153	0.491	0.106	0.410
41154	0.467	0.025	0.339
41155	0.442	-0.059	0.264
41211	0.713	0.784	0.816
41212	0.663	0.728	0.782
41213	0.650	0.713	0.773
41214	0.626	0.510	0.647
41215	0.601	0.299	0.516
41221	0.649	0.686	0.769
41222	0.599	0.629	0.721
41223	0.586	0.615	0.708
41224	0.562	0.411	0.590
41225	0.537	0.200	0.468
41231	0.633	0.661	0.757
41232	0.583	0.605	0.706
41233	0.570	0.590	0.692
41234	0.546	0.387	0.576
41235	0.521	0.176	0.456
41241	0.587	0.456	0.626
41242	0.537	0.400	0.581
41243	0.524	0.385	0.570
41244	0.500	0.231	0.475

41245	0.475	0.070	0.376
41251	0.519	0.149	0.429
41252	0.469	0.092	0.394
41253	0.456	0.078	0.386
41254	0.432	-0.004	0.322
41255	0.407	-0.088	0.256
41311	0.704	0.777	0.814
41312	0.654	0.721	0.777
41313	0.641	0.706	0.767
41314	0.617	0.503	0.643
41315	0.592	0.291	0.514
41321	0.640	0.678	0.763
41322	0.590	0.622	0.712
41323	0.577	0.607	0.699
41324	0.553	0.404	0.583
41325	0.528	0.193	0.462
41331	0.624	0.654	0.751
41332	0.574	0.598	0.696
41333	0.561	0.583	0.682
41334	0.537	0.380	0.568
41335	0.512	0.168	0.450
41341	0.579	0.449	0.621
41342	0.529	0.393	0.574
41343	0.516	0.378	0.561
41344	0.492	0.224	0.468
41345	0.467	0.063	0.371
41351	0.510	0.141	0.427
41352	0.460	0.085	0.389
41353	0.447	0.070	0.380
41354	0.423	-0.011	0.318
41355	0.398	-0.095	0.254
41411	0.675	0.676	0.744
41412	0.625	0.620	0.711
41413	0.612	0.605	0.703
41414	0.588	0.442	0.596
41415	0.563	0.272	0.485
41421	0.611	0.577	0.698
41422	0.561	0.521	0.653
41423	0.548	0.506	0.641
41424	0.524	0.343	0.542
41425	0.499	0.174	0.439
41431	0.595	0.553	0.687
41432	0.545	0.497	0.638
41433	0.532	0.482	0.625
41434	0.508	0.319	0.529
41435	0.483	0.149	0.428
41441	0.550	0.381	0.572
41442	0.500	0.325	0.530
41443	0.487	0.310	0.519

41444	0.462	0.180	0.437
41445	0.438	0.044	0.351
41451	0.481	0.122	0.398
41452	0.431	0.066	0.366
41453	0.418	0.051	0.358
41454	0.394	-0.030	0.298
41455	0.369	-0.114	0.236
41511	0.615	0.469	0.599
41512	0.565	0.413	0.578
41513	0.552	0.398	0.573
41514	0.528	0.317	0.501
41515	0.503	0.233	0.427
41521	0.551	0.371	0.565
41522	0.501	0.315	0.531
41523	0.488	0.300	0.522
41524	0.464	0.219	0.459
41525	0.439	0.135	0.393
41531	0.535	0.346	0.556
41532	0.485	0.290	0.519
41533	0.472	0.275	0.509
41534	0.448	0.194	0.448
41535	0.423	0.110	0.384
41541	0.490	0.241	0.470
41542	0.440	0.185	0.439
41543	0.427	0.170	0.431
41544	0.403	0.089	0.372
41545	0.378	0.005	0.310
41551	0.421	0.083	0.340
41552	0.371	0.027	0.320
41553	0.358	0.012	0.314
41554	0.334	-0.069	0.257
41555	0.309	-0.153	0.198
42111	0.703	0.726	0.787
42112	0.653	0.670	0.752
42113	0.640	0.655	0.743
42114	0.616	0.452	0.617
42115	0.591	0.241	0.486
42121	0.639	0.628	0.738
42122	0.589	0.572	0.690
42123	0.576	0.557	0.677
42124	0.552	0.353	0.560
42125	0.527	0.142	0.437
42131	0.623	0.603	0.726
42132	0.573	0.547	0.674
42133	0.560	0.532	0.661
42134	0.536	0.329	0.545
42135	0.511	0.118	0.425
42141	0.578	0.399	0.595
42142	0.528	0.342	0.550

42143	0.515	0.328	0.539
42144	0.491	0.173	0.444
42145	0.466	0.013	0.346
42151	0.509	0.091	0.399
42152	0.459	0.034	0.364
42153	0.446	0.020	0.355
42154	0.422	-0.061	0.292
42155	0.397	-0.145	0.227
42211	0.668	0.698	0.764
42212	0.618	0.641	0.716
42213	0.605	0.627	0.704
42214	0.581	0.423	0.586
42215	0.556	0.212	0.464
42221	0.604	0.599	0.703
42222	0.554	0.543	0.641
42223	0.541	0.528	0.624
42224	0.517	0.325	0.515
42225	0.492	0.113	0.402
42231	0.588	0.575	0.687
42232	0.538	0.518	0.622
42233	0.525	0.504	0.605
42234	0.501	0.300	0.498
42235	0.476	0.089	0.386
42241	0.543	0.370	0.563
42242	0.493	0.313	0.505
42243	0.480	0.299	0.490
42244	0.455	0.144	0.403
42245	0.431	-0.016	0.314
42251	0.474	0.062	0.377
42252	0.424	0.006	0.329
42253	0.411	-0.009	0.316
42254	0.387	-0.090	0.262
42255	0.362	-0.174	0.205
42311	0.659	0.690	0.759
42312	0.609	0.634	0.707
42313	0.596	0.619	0.694
42314	0.572	0.416	0.578
42315	0.547	0.205	0.459
42321	0.595	0.592	0.694
42322	0.545	0.536	0.629
42323	0.532	0.521	0.612
42324	0.508	0.317	0.504
42325	0.483	0.106	0.393
42331	0.579	0.567	0.678
42332	0.529	0.511	0.609
42333	0.516	0.496	0.591
42334	0.492	0.293	0.486
42335	0.467	0.082	0.377
42341	0.534	0.363	0.555

42342	0.484	0.306	0.494
42343	0.471	0.292	0.477
42344	0.447	0.137	0.393
42345	0.422	-0.023	0.306
42351	0.465	0.055	0.372
42352	0.415	-0.002	0.320
42353	0.402	-0.016	0.307
42354	0.378	-0.097	0.254
42355	0.353	-0.181	0.200
42411	0.630	0.589	0.694
42412	0.580	0.533	0.648
42413	0.567	0.518	0.636
42414	0.543	0.355	0.538
42415	0.518	0.186	0.436
42421	0.566	0.491	0.635
42422	0.516	0.434	0.575
42423	0.503	0.420	0.559
42424	0.479	0.257	0.469
42425	0.454	0.087	0.376
42431	0.550	0.466	0.620
42432	0.500	0.410	0.557
42433	0.487	0.395	0.540
42434	0.463	0.232	0.452
42435	0.438	0.063	0.361
42441	0.505	0.294	0.512
42442	0.455	0.238	0.455
42443	0.442	0.223	0.441
42444	0.418	0.093	0.367
42445	0.393	-0.042	0.291
42451	0.436	0.036	0.349
42452	0.386	-0.021	0.303
42453	0.373	-0.035	0.291
42454	0.349	-0.116	0.240
42455	0.324	-0.200	0.187
42511	0.570	0.383	0.562
42512	0.520	0.326	0.527
42513	0.507	0.312	0.518
42514	0.483	0.231	0.455
42515	0.458	0.147	0.390
42521	0.506	0.284	0.513
42522	0.456	0.228	0.465
42523	0.443	0.213	0.452
42524	0.419	0.132	0.398
42525	0.394	0.048	0.341
42531	0.490	0.260	0.501
42532	0.440	0.203	0.449
42533	0.427	0.189	0.436
42534	0.403	0.108	0.383
42535	0.378	0.024	0.329

42541	0.445	0.155	0.422
42542	0.395	0.098	0.377
42543	0.382	0.084	0.365
42544	0.358	0.003	0.314
42545	0.333	-0.081	0.261
42551	0.376	-0.003	0.303
42552	0.326	-0.060	0.268
42553	0.313	-0.074	0.259
42554	0.289	-0.155	0.210
42555	0.264	-0.239	0.160
43111	0.694	0.709	0.779
43112	0.644	0.653	0.741
43113	0.631	0.638	0.732
43114	0.607	0.435	0.607
43115	0.582	0.223	0.478
43121	0.630	0.610	0.728
43122	0.580	0.554	0.677
43123	0.567	0.539	0.663
43124	0.543	0.336	0.547
43125	0.518	0.125	0.427
43131	0.614	0.586	0.715
43132	0.564	0.530	0.660
43133	0.551	0.515	0.646
43134	0.527	0.312	0.533
43135	0.502	0.100	0.414
43141	0.569	0.381	0.585
43142	0.519	0.325	0.538
43143	0.506	0.310	0.525
43144	0.482	0.156	0.433
43145	0.457	-0.005	0.336
43151	0.500	0.073	0.391
43152	0.450	0.017	0.353
43153	0.437	0.002	0.344
43154	0.413	-0.079	0.282
43155	0.388	-0.163	0.219
43211	0.659	0.680	0.754
43212	0.609	0.624	0.703
43213	0.596	0.609	0.690
43214	0.572	0.406	0.574
43215	0.547	0.195	0.454
43221	0.595	0.582	0.689
43222	0.545	0.525	0.625
43223	0.532	0.511	0.608
43224	0.508	0.307	0.500
43225	0.483	0.096	0.389
43231	0.579	0.557	0.673
43232	0.529	0.501	0.605
43233	0.516	0.486	0.587
43234	0.492	0.283	0.482

43235	0.467	0.072	0.372
43241	0.533	0.352	0.551
43242	0.483	0.296	0.489
43243	0.470	0.281	0.473
43244	0.446	0.127	0.389
43245	0.421	-0.034	0.301
43251	0.465	0.045	0.367
43252	0.415	-0.012	0.316
43253	0.402	-0.027	0.302
43254	0.378	-0.108	0.249
43255	0.353	-0.192	0.195
43311	0.650	0.673	0.748
43312	0.600	0.617	0.693
43313	0.587	0.602	0.679
43314	0.563	0.399	0.566
43315	0.538	0.187	0.448
43321	0.586	0.574	0.680
43322	0.536	0.518	0.612
43323	0.523	0.503	0.594
43324	0.499	0.300	0.488
43325	0.474	0.089	0.379
43331	0.570	0.550	0.663
43332	0.520	0.494	0.591
43333	0.507	0.479	0.573
43334	0.483	0.276	0.469
43335	0.458	0.064	0.362
43341	0.525	0.345	0.542
43342	0.475	0.289	0.477
43343	0.462	0.274	0.461
43344	0.438	0.120	0.378
43345	0.413	-0.041	0.293
43351	0.456	0.037	0.361
43352	0.406	-0.019	0.306
43353	0.393	-0.034	0.292
43354	0.369	-0.115	0.241
43355	0.344	-0.199	0.189
43411	0.621	0.572	0.684
43412	0.571	0.516	0.635
43413	0.558	0.501	0.623
43414	0.534	0.338	0.526
43415	0.509	0.168	0.426
43421	0.557	0.473	0.622
43422	0.507	0.417	0.559
43423	0.494	0.402	0.543
43424	0.470	0.239	0.455
43425	0.445	0.070	0.363
43431	0.541	0.449	0.606
43432	0.491	0.393	0.540
43433	0.478	0.378	0.523

43434	0.454	0.215	0.437
43435	0.429	0.045	0.347
43441	0.496	0.277	0.500
43442	0.446	0.221	0.440
43443	0.433	0.206	0.425
43444	0.408	0.076	0.353
43445	0.384	-0.060	0.279
43451	0.427	0.018	0.339
43452	0.377	-0.038	0.290
43453	0.364	-0.053	0.277
43454	0.340	-0.134	0.228
43455	0.315	-0.218	0.177
43511	0.561	0.365	0.554
43512	0.511	0.309	0.516
43513	0.498	0.294	0.507
43514	0.474	0.213	0.445
43515	0.449	0.129	0.382
43521	0.497	0.267	0.503
43522	0.447	0.211	0.452
43523	0.434	0.196	0.438
43524	0.410	0.115	0.385
43525	0.385	0.031	0.330
43531	0.481	0.242	0.490
43532	0.431	0.186	0.435
43533	0.418	0.171	0.421
43534	0.394	0.090	0.370
43535	0.369	0.006	0.318
43541	0.436	0.137	0.412
43542	0.386	0.081	0.364
43543	0.373	0.066	0.352
43544	0.349	-0.015	0.303
43545	0.324	-0.099	0.252
43551	0.367	-0.021	0.295
43552	0.317	-0.077	0.257
43553	0.304	-0.092	0.248
43554	0.280	-0.173	0.201
43555	0.255	-0.257	0.152
44111	0.683	0.622	0.712
44112	0.633	0.565	0.678
44113	0.620	0.551	0.669
44114	0.596	0.377	0.558
44115	0.571	0.197	0.442
44121	0.619	0.523	0.664
44122	0.569	0.467	0.618
44123	0.556	0.452	0.605
44124	0.532	0.278	0.502
44125	0.507	0.098	0.395
44131	0.603	0.499	0.653
44132	0.553	0.442	0.602

44133	0.540	0.428	0.589
44134	0.516	0.254	0.488
44135	0.491	0.074	0.384
44141	0.557	0.318	0.534
44142	0.507	0.262	0.490
44143	0.494	0.247	0.479
44144	0.470	0.110	0.394
44145	0.445	-0.032	0.306
44151	0.489	0.047	0.355
44152	0.439	-0.010	0.322
44153	0.426	-0.024	0.313
44154	0.402	-0.105	0.253
44155	0.377	-0.189	0.190
44211	0.647	0.593	0.691
44212	0.597	0.536	0.644
44213	0.584	0.522	0.632
44214	0.560	0.348	0.529
44215	0.535	0.168	0.422
44221	0.583	0.494	0.630
44222	0.533	0.438	0.570
44223	0.520	0.423	0.554
44224	0.496	0.249	0.459
44225	0.471	0.069	0.361
44231	0.567	0.470	0.615
44232	0.517	0.413	0.551
44233	0.504	0.399	0.535
44234	0.480	0.225	0.442
44235	0.455	0.045	0.346
44241	0.522	0.289	0.503
44242	0.472	0.233	0.446
44243	0.459	0.218	0.431
44244	0.435	0.082	0.355
44245	0.410	-0.060	0.276
44251	0.453	0.018	0.335
44252	0.403	-0.039	0.288
44253	0.390	-0.053	0.276
44254	0.366	-0.134	0.224
44255	0.341	-0.218	0.170
44311	0.639	0.586	0.686
44312	0.589	0.529	0.636
44313	0.576	0.515	0.622
44314	0.552	0.341	0.521
44315	0.527	0.161	0.417
44321	0.575	0.487	0.622
44322	0.525	0.431	0.558
44323	0.512	0.416	0.541
44324	0.488	0.242	0.449
44325	0.463	0.062	0.352
44331	0.559	0.463	0.606

44332	0.509	0.406	0.539
44333	0.496	0.392	0.521
44334	0.472	0.218	0.430
44335	0.447	0.038	0.336
44341	0.513	0.282	0.496
44342	0.463	0.226	0.435
44343	0.450	0.211	0.419
44344	0.426	0.074	0.345
44345	0.401	-0.068	0.268
44351	0.445	0.011	0.330
44352	0.395	-0.046	0.279
44353	0.382	-0.060	0.266
44354	0.358	-0.141	0.217
44355	0.333	-0.225	0.165
44411	0.609	0.504	0.631
44412	0.559	0.448	0.586
44413	0.546	0.433	0.574
44414	0.522	0.290	0.487
44415	0.497	0.142	0.396
44421	0.545	0.406	0.572
44422	0.495	0.350	0.514
44423	0.482	0.335	0.499
44424	0.458	0.192	0.419
44425	0.433	0.043	0.337
44431	0.529	0.381	0.558
44432	0.479	0.325	0.496
44433	0.466	0.310	0.480
44434	0.442	0.167	0.403
44435	0.417	0.019	0.322
44441	0.484	0.226	0.458
44442	0.434	0.169	0.403
44443	0.421	0.155	0.389
44444	0.397	0.036	0.323
44445	0.372	-0.087	0.255
44451	0.415	-0.009	0.309
44452	0.365	-0.065	0.264
44453	0.352	-0.080	0.252
44454	0.328	-0.160	0.204
44455	0.303	-0.245	0.154
44511	0.550	0.339	0.518
44512	0.500	0.282	0.485
44513	0.487	0.268	0.476
44514	0.463	0.187	0.416
44515	0.438	0.103	0.353
44521	0.486	0.240	0.471
44522	0.436	0.184	0.424
44523	0.423	0.169	0.411
44524	0.399	0.088	0.360
44525	0.374	0.004	0.306

44531	0.470	0.216	0.460
44532	0.420	0.159	0.409
44533	0.407	0.145	0.395
44534	0.383	0.064	0.346
44535	0.358	-0.020	0.294
44541	0.424	0.111	0.382
44542	0.374	0.054	0.338
44543	0.361	0.040	0.327
44544	0.337	-0.041	0.279
44545	0.312	-0.126	0.229
44551	0.356	-0.047	0.266
44552	0.306	-0.104	0.233
44553	0.293	-0.118	0.224
44554	0.269	-0.199	0.178
44555	0.244	-0.283	0.131
45111	0.646	0.349	0.502
45112	0.596	0.293	0.481
45113	0.583	0.278	0.476
45114	0.559	0.197	0.404
45115	0.534	0.113	0.330
45121	0.582	0.251	0.468
45122	0.532	0.195	0.434
45123	0.519	0.180	0.425
45124	0.495	0.099	0.362
45125	0.470	0.015	0.296
45131	0.566	0.226	0.459
45132	0.516	0.170	0.422
45133	0.503	0.155	0.412
45134	0.479	0.074	0.351
45135	0.454	-0.010	0.287
45141	0.521	0.121	0.373
45142	0.471	0.065	0.342
45143	0.458	0.050	0.334
45144	0.434	-0.031	0.275
45145	0.409	-0.115	0.213
45151	0.452	-0.037	0.243
45152	0.402	-0.093	0.223
45153	0.389	-0.108	0.217
45154	0.365	-0.189	0.160
45155	0.340	-0.273	0.101
45211	0.611	0.321	0.495
45212	0.561	0.264	0.460
45213	0.548	0.250	0.452
45214	0.524	0.169	0.388
45215	0.499	0.085	0.322
45221	0.547	0.222	0.447
45222	0.497	0.166	0.399
45223	0.484	0.151	0.387
45224	0.460	0.070	0.332

45225	0.435	-0.014	0.274
45231	0.531	0.198	0.435
45232	0.481	0.141	0.384
45233	0.468	0.127	0.370
45234	0.444	0.046	0.318
45235	0.419	-0.039	0.263
45241	0.485	0.092	0.355
45242	0.435	0.036	0.311
45243	0.422	0.021	0.299
45244	0.398	-0.060	0.248
45245	0.373	-0.144	0.195
45251	0.417	-0.066	0.235
45252	0.367	-0.122	0.201
45253	0.354	-0.137	0.193
45254	0.330	-0.218	0.144
45255	0.305	-0.302	0.093
45311	0.602	0.313	0.493
45312	0.552	0.257	0.455
45313	0.539	0.242	0.446
45314	0.515	0.161	0.384
45315	0.490	0.077	0.320
45321	0.538	0.215	0.441
45322	0.488	0.159	0.390
45323	0.475	0.144	0.377
45324	0.451	0.063	0.324
45325	0.426	-0.021	0.269
45331	0.522	0.190	0.429
45332	0.472	0.134	0.374
45333	0.459	0.119	0.360
45334	0.435	0.038	0.309
45335	0.410	-0.046	0.257
45341	0.477	0.085	0.350
45342	0.427	0.029	0.303
45343	0.414	0.014	0.291
45344	0.390	-0.067	0.242
45345	0.365	-0.151	0.191
45351	0.408	-0.073	0.233
45352	0.358	-0.129	0.196
45353	0.345	-0.144	0.187
45354	0.321	-0.225	0.140
45355	0.296	-0.309	0.091
45411	0.573	0.294	0.464
45412	0.523	0.238	0.432
45413	0.510	0.223	0.424
45414	0.486	0.142	0.364
45415	0.461	0.058	0.302
45421	0.509	0.196	0.418
45422	0.459	0.139	0.373
45423	0.446	0.125	0.361

45424	0.422	0.044	0.310
45425	0.397	-0.040	0.256
45431	0.493	0.171	0.407
45432	0.443	0.115	0.358
45433	0.430	0.100	0.345
45434	0.406	0.019	0.296
45435	0.381	-0.065	0.245
45441	0.448	0.066	0.330
45442	0.398	0.010	0.288
45443	0.385	-0.005	0.277
45444	0.360	-0.086	0.229
45445	0.336	-0.170	0.180
45451	0.379	-0.092	0.215
45452	0.329	-0.148	0.183
45453	0.316	-0.163	0.175
45454	0.292	-0.244	0.129
45455	0.267	-0.328	0.082
45511	0.513	0.255	0.406
45512	0.463	0.199	0.386
45513	0.450	0.184	0.380
45514	0.426	0.103	0.323
45515	0.401	0.019	0.263
45521	0.449	0.157	0.372
45522	0.399	0.101	0.337
45523	0.386	0.086	0.328
45524	0.362	0.005	0.280
45525	0.337	-0.079	0.229
45531	0.433	0.132	0.363
45532	0.383	0.076	0.325
45533	0.370	0.061	0.316
45534	0.346	-0.020	0.269
45535	0.321	-0.104	0.220
45541	0.388	0.027	0.289
45542	0.338	-0.029	0.258
45543	0.325	-0.044	0.250
45544	0.301	-0.125	0.205
45545	0.276	-0.209	0.158
45551	0.319	-0.131	0.177
45552	0.269	-0.187	0.156
45553	0.256	-0.202	0.150
45554	0.232	-0.283	0.108
45555	0.207	-0.367	0.064
51111	0.430	0.336	0.442
51112	0.380	0.280	0.429
51113	0.367	0.265	0.426
51114	0.343	0.184	0.349
51115	0.318	0.100	0.268
51121	0.366	0.238	0.416
51122	0.316	0.181	0.396

51123	0.303	0.167	0.391
51124	0.279	0.086	0.318
51125	0.254	0.002	0.242
51131	0.350	0.213	0.409
51132	0.300	0.157	0.388
51133	0.287	0.142	0.382
51134	0.263	0.061	0.310
51135	0.238	-0.023	0.235
51141	0.305	0.108	0.318
51142	0.255	0.052	0.300
51143	0.242	0.037	0.295
51144	0.217	-0.044	0.227
51145	0.193	-0.128	0.156
51151	0.236	-0.050	0.181
51152	0.186	-0.106	0.168
51153	0.173	-0.121	0.165
51154	0.149	-0.202	0.102
51155	0.124	-0.286	0.037
51211	0.395	0.307	0.442
51212	0.345	0.251	0.422
51213	0.332	0.236	0.417
51214	0.308	0.155	0.344
51215	0.283	0.071	0.268
51221	0.331	0.209	0.409
51222	0.281	0.152	0.377
51223	0.268	0.138	0.368
51224	0.244	0.057	0.303
51225	0.219	-0.027	0.235
51231	0.315	0.184	0.400
51232	0.265	0.128	0.365
51233	0.252	0.113	0.356
51234	0.228	0.032	0.293
51235	0.203	-0.052	0.226
51241	0.269	0.079	0.313
51242	0.219	0.023	0.284
51243	0.206	0.008	0.276
51244	0.182	-0.073	0.215
51245	0.157	-0.157	0.150
51251	0.201	-0.079	0.181
51252	0.151	-0.135	0.161
51253	0.138	-0.150	0.156
51254	0.114	-0.231	0.097
51255	0.089	-0.315	0.036
51311	0.386	0.300	0.442
51312	0.336	0.244	0.421
51313	0.323	0.229	0.415
51314	0.299	0.148	0.343
51315	0.274	0.064	0.268
51321	0.322	0.202	0.407

51322	0.272	0.145	0.372
51323	0.259	0.131	0.363
51324	0.235	0.050	0.299
51325	0.210	-0.035	0.233
51331	0.306	0.177	0.398
51332	0.256	0.121	0.360
51333	0.243	0.106	0.350
51334	0.219	0.025	0.288
51335	0.194	-0.059	0.224
51341	0.261	0.072	0.311
51342	0.211	0.016	0.280
51343	0.198	0.001	0.272
51344	0.173	-0.080	0.211
51345	0.149	-0.164	0.149
51351	0.192	-0.086	0.181
51352	0.142	-0.142	0.160
51353	0.129	-0.157	0.154
51354	0.105	-0.238	0.096
51355	0.080	-0.322	0.036
51411	0.357	0.281	0.410
51412	0.307	0.225	0.391
51413	0.294	0.210	0.386
51414	0.270	0.129	0.317
51415	0.245	0.045	0.245
51421	0.293	0.182	0.378
51422	0.243	0.126	0.347
51423	0.230	0.111	0.340
51424	0.206	0.030	0.277
51425	0.181	-0.054	0.213
51431	0.277	0.158	0.369
51432	0.227	0.102	0.337
51433	0.214	0.087	0.328
51434	0.190	0.006	0.268
51435	0.165	-0.078	0.205
51441	0.231	0.053	0.285
51442	0.181	-0.003	0.258
51443	0.168	-0.018	0.251
51444	0.144	-0.099	0.193
51445	0.119	-0.183	0.132
51451	0.163	-0.105	0.158
51452	0.113	-0.161	0.140
51453	0.100	-0.176	0.135
51454	0.076	-0.257	0.080
51455	0.051	-0.341	0.023
51511	0.297	0.242	0.344
51512	0.247	0.186	0.331
51513	0.234	0.171	0.327
51514	0.210	0.090	0.264
51515	0.185	0.006	0.199

51521	0.233	0.144	0.318
51522	0.183	0.087	0.297
51523	0.170	0.073	0.292
51524	0.146	-0.009	0.233
51525	0.121	-0.093	0.173
51531	0.217	0.119	0.311
51532	0.167	0.063	0.289
51533	0.154	0.048	0.283
51534	0.130	-0.033	0.226
51535	0.105	-0.117	0.166
51541	0.172	0.014	0.232
51542	0.122	-0.042	0.213
51543	0.109	-0.057	0.208
51544	0.084	-0.138	0.154
51545	0.060	-0.222	0.099
51551	0.103	-0.144	0.112
51552	0.053	-0.200	0.099
51553	0.040	-0.215	0.096
51554	0.016	-0.296	0.047
51555	-0.009	-0.380	-0.003
52111	0.385	0.249	0.413
52112	0.335	0.193	0.392
52113	0.322	0.178	0.387
52114	0.298	0.097	0.314
52115	0.273	0.013	0.238
52121	0.321	0.151	0.379
52122	0.271	0.095	0.346
52123	0.258	0.080	0.338
52124	0.234	-0.001	0.272
52125	0.209	-0.085	0.204
52131	0.305	0.126	0.371
52132	0.255	0.070	0.335
52133	0.242	0.055	0.325
52134	0.218	-0.026	0.262
52135	0.193	-0.110	0.196
52141	0.260	0.021	0.283
52142	0.210	-0.035	0.253
52143	0.197	-0.050	0.246
52144	0.173	-0.131	0.184
52145	0.148	-0.215	0.120
52151	0.191	-0.137	0.151
52152	0.141	-0.193	0.131
52153	0.128	-0.208	0.126
52154	0.104	-0.289	0.068
52155	0.079	-0.373	0.007
52211	0.350	0.221	0.406
52212	0.300	0.164	0.373
52213	0.287	0.150	0.364
52214	0.263	0.069	0.299

52215	0.238	-0.016	0.231
52221	0.286	0.122	0.359
52222	0.236	0.066	0.313
52223	0.223	0.051	0.301
52224	0.199	-0.030	0.244
52225	0.174	-0.114	0.185
52231	0.270	0.098	0.347
52232	0.220	0.041	0.298
52233	0.207	0.027	0.285
52234	0.183	-0.054	0.230
52235	0.158	-0.139	0.173
52241	0.224	-0.008	0.266
52242	0.174	-0.064	0.223
52243	0.161	-0.079	0.212
52244	0.137	-0.160	0.159
52245	0.112	-0.244	0.104
52251	0.156	-0.166	0.144
52252	0.106	-0.222	0.112
52253	0.093	-0.237	0.103
52254	0.069	-0.317	0.052
52255	0.044	-0.402	-0.001
52311	0.341	0.213	0.404
52312	0.291	0.157	0.368
52313	0.278	0.142	0.358
52314	0.254	0.061	0.295
52315	0.229	-0.023	0.230
52321	0.277	0.115	0.354
52322	0.227	0.059	0.305
52323	0.214	0.044	0.292
52324	0.190	-0.037	0.237
52325	0.165	-0.121	0.180
52331	0.261	0.090	0.341
52332	0.211	0.034	0.289
52333	0.198	0.019	0.275
52334	0.174	-0.062	0.222
52335	0.149	-0.146	0.167
52341	0.216	-0.015	0.262
52342	0.166	-0.071	0.216
52343	0.153	-0.086	0.204
52344	0.129	-0.167	0.153
52345	0.104	-0.251	0.100
52351	0.147	-0.173	0.143
52352	0.097	-0.229	0.107
52353	0.084	-0.244	0.097
52354	0.060	-0.325	0.049
52355	0.035	-0.409	-0.002
52411	0.312	0.194	0.374
52412	0.262	0.138	0.344
52413	0.249	0.123	0.336

52414	0.225	0.042	0.274
52415	0.200	-0.042	0.210
52421	0.248	0.096	0.330
52422	0.198	0.040	0.286
52423	0.185	0.025	0.275
52424	0.161	-0.056	0.221
52425	0.136	-0.140	0.165
52431	0.232	0.071	0.319
52432	0.182	0.015	0.272
52433	0.169	0.000	0.259
52434	0.145	-0.081	0.208
52435	0.120	-0.165	0.154
52441	0.186	-0.034	0.240
52442	0.136	-0.090	0.200
52443	0.123	-0.105	0.189
52444	0.099	-0.186	0.140
52445	0.074	-0.270	0.088
52451	0.118	-0.192	0.123
52452	0.068	-0.248	0.092
52453	0.055	-0.263	0.084
52454	0.031	-0.344	0.037
52455	0.006	-0.428	-0.012
52511	0.252	0.155	0.314
52512	0.202	0.099	0.294
52513	0.189	0.084	0.289
52514	0.165	0.003	0.230
52515	0.140	-0.081	0.170
52521	0.188	0.057	0.280
52522	0.138	0.001	0.248
52523	0.125	-0.014	0.239
52524	0.101	-0.095	0.189
52525	0.076	-0.179	0.136
52531	0.172	0.032	0.272
52532	0.122	-0.024	0.236
52533	0.109	-0.039	0.227
52534	0.085	-0.120	0.178
52535	0.060	-0.204	0.128
52541	0.127	-0.073	0.196
52542	0.077	-0.129	0.167
52543	0.064	-0.144	0.159
52544	0.040	-0.225	0.112
52545	0.015	-0.309	0.064
52551	0.058	-0.231	0.083
52552	0.008	-0.287	0.062
52553	-0.005	-0.302	0.057
52554	-0.029	-0.383	0.013
52555	-0.054	-0.467	-0.032
53111	0.376	0.232	0.407
53112	0.326	0.176	0.385

53113	0.313	0.161	0.379
53114	0.289	0.080	0.307
53115	0.264	-0.004	0.232
53121	0.312	0.134	0.372
53122	0.262	0.077	0.336
53123	0.249	0.063	0.327
53124	0.225	-0.019	0.263
53125	0.200	-0.103	0.197
53131	0.296	0.109	0.363
53132	0.246	0.053	0.324
53133	0.233	0.038	0.314
53134	0.209	-0.043	0.252
53135	0.184	-0.127	0.188
53141	0.251	0.004	0.276
53142	0.201	-0.052	0.244
53143	0.188	-0.067	0.236
53144	0.163	-0.148	0.176
53145	0.139	-0.232	0.113
53151	0.182	-0.154	0.145
53152	0.132	-0.210	0.124
53153	0.119	-0.225	0.118
53154	0.095	-0.306	0.061
53155	0.070	-0.390	0.001
53211	0.341	0.203	0.398
53212	0.291	0.147	0.363
53213	0.278	0.132	0.353
53214	0.254	0.051	0.290
53215	0.229	-0.033	0.224
53221	0.277	0.105	0.349
53222	0.227	0.048	0.300
53223	0.214	0.034	0.287
53224	0.190	-0.047	0.232
53225	0.165	-0.131	0.175
53231	0.261	0.080	0.337
53232	0.211	0.024	0.284
53233	0.198	0.009	0.271
53234	0.174	-0.072	0.218
53235	0.149	-0.156	0.162
53241	0.215	-0.025	0.257
53242	0.165	-0.081	0.211
53243	0.152	-0.096	0.199
53244	0.128	-0.177	0.148
53245	0.103	-0.261	0.094
53251	0.147	-0.183	0.137
53252	0.097	-0.239	0.102
53253	0.084	-0.254	0.092
53254	0.060	-0.335	0.043
53255	0.035	-0.419	-0.008
53311	0.332	0.196	0.396

53312	0.282	0.140	0.357
53313	0.269	0.125	0.347
53314	0.245	0.044	0.286
53315	0.220	-0.040	0.222
53321	0.268	0.098	0.343
53322	0.218	0.041	0.291
53323	0.205	0.027	0.277
53324	0.181	-0.055	0.224
53325	0.156	-0.139	0.169
53331	0.252	0.073	0.330
53332	0.202	0.017	0.275
53333	0.189	0.002	0.260
53334	0.165	-0.079	0.209
53335	0.140	-0.163	0.156
53341	0.207	-0.032	0.252
53342	0.157	-0.088	0.203
53343	0.144	-0.103	0.191
53344	0.119	-0.184	0.141
53345	0.095	-0.268	0.090
53351	0.138	-0.190	0.135
53352	0.088	-0.246	0.096
53353	0.075	-0.261	0.086
53354	0.051	-0.342	0.039
53355	0.026	-0.426	-0.010
53411	0.303	0.177	0.367
53412	0.253	0.121	0.334
53413	0.240	0.106	0.325
53414	0.216	0.025	0.265
53415	0.191	-0.059	0.203
53421	0.239	0.078	0.320
53422	0.189	0.022	0.274
53423	0.176	0.007	0.261
53424	0.152	-0.074	0.210
53425	0.127	-0.158	0.156
53431	0.223	0.054	0.308
53432	0.173	-0.002	0.259
53433	0.160	-0.017	0.246
53434	0.136	-0.098	0.196
53435	0.111	-0.182	0.144
53441	0.177	-0.051	0.232
53442	0.127	-0.107	0.188
53443	0.114	-0.122	0.177
53444	0.090	-0.203	0.129
53445	0.065	-0.287	0.079
53451	0.109	-0.209	0.116
53452	0.059	-0.265	0.083
53453	0.046	-0.280	0.074
53454	0.022	-0.361	0.028
53455	-0.003	-0.445	-0.019

53511	0.243	0.138	0.308
53512	0.193	0.082	0.287
53513	0.180	0.067	0.281
53514	0.156	-0.014	0.224
53515	0.131	-0.098	0.164
53521	0.179	0.040	0.273
53522	0.129	-0.017	0.238
53523	0.116	-0.032	0.229
53524	0.092	-0.113	0.180
53525	0.067	-0.197	0.129
53531	0.163	0.015	0.264
53532	0.113	-0.041	0.226
53533	0.100	-0.056	0.216
53534	0.076	-0.137	0.169
53535	0.051	-0.221	0.120
53541	0.118	-0.090	0.189
53542	0.068	-0.146	0.158
53543	0.055	-0.161	0.149
53544	0.030	-0.242	0.104
53545	0.006	-0.326	0.057
53551	0.049	-0.248	0.077
53552	-0.001	-0.304	0.055
53553	-0.014	-0.319	0.049
53554	-0.038	-0.400	0.006
53555	-0.063	-0.484	-0.038
54111	0.364	0.205	0.368
54112	0.314	0.149	0.348
54113	0.301	0.134	0.343
54114	0.277	0.053	0.273
54115	0.252	-0.031	0.200
54121	0.300	0.107	0.335
54122	0.250	0.050	0.303
54123	0.237	0.036	0.295
54124	0.213	-0.045	0.232
54125	0.188	-0.129	0.167
54131	0.284	0.082	0.327
54132	0.234	0.026	0.292
54133	0.221	0.011	0.283
54134	0.197	-0.070	0.222
54135	0.172	-0.154	0.159
54141	0.239	-0.023	0.242
54142	0.189	-0.079	0.213
54143	0.176	-0.094	0.206
54144	0.152	-0.175	0.147
54145	0.127	-0.259	0.086
54151	0.170	-0.181	0.114
54152	0.120	-0.237	0.094
54153	0.107	-0.252	0.089
54154	0.083	-0.333	0.034

54155	0.058	-0.417	-0.024
54211	0.329	0.176	0.361
54212	0.279	0.120	0.330
54213	0.266	0.105	0.321
54214	0.242	0.024	0.259
54215	0.217	-0.060	0.194
54221	0.265	0.078	0.316
54222	0.215	0.022	0.271
54223	0.202	0.007	0.259
54224	0.178	-0.074	0.205
54225	0.153	-0.158	0.149
54231	0.249	0.053	0.305
54232	0.199	-0.003	0.256
54233	0.186	-0.018	0.244
54234	0.162	-0.099	0.192
54235	0.137	-0.183	0.138
54241	0.204	-0.052	0.226
54242	0.154	-0.108	0.184
54243	0.141	-0.123	0.173
54244	0.117	-0.204	0.123
54245	0.092	-0.288	0.071
54251	0.135	-0.210	0.107
54252	0.085	-0.266	0.076
54253	0.072	-0.281	0.068
54254	0.048	-0.362	0.020
54255	0.023	-0.446	-0.030
54311	0.320	0.169	0.360
54312	0.270	0.113	0.325
54313	0.257	0.098	0.316
54314	0.233	0.017	0.256
54315	0.208	-0.067	0.193
54321	0.256	0.071	0.311
54322	0.206	0.014	0.263
54323	0.193	0.000	0.251
54324	0.169	-0.081	0.198
54325	0.144	-0.165	0.144
54331	0.240	0.046	0.299
54332	0.190	-0.010	0.248
54333	0.177	-0.025	0.234
54334	0.153	-0.106	0.184
54335	0.128	-0.190	0.132
54341	0.195	-0.059	0.222
54342	0.145	-0.115	0.177
54343	0.132	-0.130	0.166
54344	0.108	-0.211	0.117
54345	0.083	-0.295	0.067
54351	0.126	-0.217	0.106
54352	0.076	-0.273	0.071
54353	0.063	-0.288	0.062

54354	0.039	-0.369	0.016
54355	0.014	-0.453	-0.032
54411	0.291	0.150	0.332
54412	0.241	0.094	0.303
54413	0.228	0.079	0.295
54414	0.204	-0.002	0.236
54415	0.179	-0.086	0.175
54421	0.227	0.052	0.289
54422	0.177	-0.005	0.246
54423	0.164	-0.019	0.235
54424	0.140	-0.100	0.185
54425	0.115	-0.184	0.132
54431	0.211	0.027	0.278
54432	0.161	-0.029	0.232
54433	0.148	-0.044	0.220
54434	0.124	-0.125	0.172
54435	0.099	-0.209	0.121
54441	0.166	-0.078	0.202
54442	0.116	-0.134	0.163
54443	0.103	-0.149	0.153
54444	0.079	-0.230	0.106
54445	0.054	-0.314	0.057
54451	0.097	-0.236	0.088
54452	0.047	-0.292	0.059
54453	0.034	-0.307	0.051
54454	0.010	-0.388	0.006
54455	-0.015	-0.472	-0.040
54511	0.231	0.111	0.276
54512	0.181	0.055	0.257
54513	0.168	0.040	0.252
54514	0.144	-0.041	0.197
54515	0.119	-0.125	0.140
54521	0.167	0.013	0.243
54522	0.117	-0.044	0.212
54523	0.104	-0.058	0.204
54524	0.080	-0.139	0.156
54525	0.055	-0.223	0.106
54531	0.151	-0.012	0.235
54532	0.101	-0.068	0.201
54533	0.088	-0.083	0.192
54534	0.064	-0.164	0.146
54535	0.039	-0.248	0.098
54541	0.106	-0.117	0.162
54542	0.056	-0.173	0.134
54543	0.043	-0.188	0.126
54544	0.019	-0.269	0.082
54545	-0.006	-0.353	0.037
54551	0.037	-0.275	0.053
54552	-0.013	-0.331	0.033

54553	-0.026	-0.346	0.027
54554	-0.050	-0.427	-0.013
54555	-0.075	-0.511	-0.055
55111	0.328	0.122	0.247
55112	0.278	0.066	0.234
55113	0.265	0.051	0.230
55114	0.241	-0.030	0.167
55115	0.216	-0.114	0.102
55121	0.264	0.024	0.221
55122	0.214	-0.033	0.200
55123	0.201	-0.048	0.195
55124	0.177	-0.129	0.136
55125	0.152	-0.213	0.076
55131	0.248	-0.001	0.214
55132	0.198	-0.057	0.192
55133	0.185	-0.072	0.186
55134	0.161	-0.153	0.129
55135	0.136	-0.237	0.069
55141	0.203	-0.106	0.135
55142	0.153	-0.162	0.116
55143	0.140	-0.177	0.111
55144	0.115	-0.258	0.057
55145	0.091	-0.342	0.002
55151	0.134	-0.264	0.016
55152	0.084	-0.320	0.003
55153	0.071	-0.335	-0.001
55154	0.047	-0.416	-0.050
55155	0.022	-0.500	-0.100
55211	0.293	0.093	0.247
55212	0.243	0.037	0.227
55213	0.230	0.022	0.222
55214	0.206	-0.059	0.163
55215	0.181	-0.143	0.102
55221	0.229	-0.005	0.214
55222	0.179	-0.062	0.181
55223	0.166	-0.076	0.173
55224	0.142	-0.157	0.122
55225	0.117	-0.241	0.069
55231	0.213	-0.030	0.205
55232	0.163	-0.086	0.170
55233	0.150	-0.101	0.160
55234	0.126	-0.182	0.111
55235	0.101	-0.266	0.060
55241	0.167	-0.135	0.129
55242	0.117	-0.191	0.100
55243	0.104	-0.206	0.092
55244	0.080	-0.287	0.045
55245	0.055	-0.371	-0.004
55251	0.099	-0.293	0.015

55252	0.049	-0.349	-0.005
55253	0.036	-0.364	-0.010
55254	0.012	-0.445	-0.054
55255	-0.013	-0.529	-0.100
55311	0.284	0.086	0.247
55312	0.234	0.030	0.226
55313	0.221	0.015	0.220
55314	0.197	-0.066	0.162
55315	0.172	-0.150	0.102
55321	0.220	-0.013	0.212
55322	0.170	-0.069	0.176
55323	0.157	-0.084	0.167
55324	0.133	-0.165	0.118
55325	0.108	-0.249	0.067
55331	0.204	-0.037	0.203
55332	0.154	-0.093	0.164
55333	0.141	-0.108	0.154
55334	0.117	-0.189	0.107
55335	0.092	-0.273	0.058
55341	0.159	-0.142	0.128
55342	0.109	-0.198	0.096
55343	0.096	-0.213	0.088
55344	0.071	-0.294	0.042
55345	0.047	-0.378	-0.005
55351	0.090	-0.300	0.015
55352	0.040	-0.356	-0.006
55353	0.027	-0.371	-0.012
55354	0.003	-0.452	-0.055
55355	-0.022	-0.536	-0.100
55411	0.255	0.067	0.224
55412	0.205	0.011	0.206
55413	0.192	-0.004	0.201
55414	0.168	-0.085	0.146
55415	0.143	-0.169	0.089
55421	0.191	-0.032	0.192
55422	0.141	-0.088	0.162
55423	0.128	-0.103	0.154
55424	0.104	-0.184	0.106
55425	0.079	-0.268	0.057
55431	0.175	-0.056	0.184
55432	0.125	-0.112	0.151
55433	0.112	-0.127	0.142
55434	0.088	-0.208	0.096
55435	0.063	-0.292	0.049
55441	0.129	-0.161	0.111
55442	0.079	-0.217	0.084
55443	0.066	-0.232	0.077
55444	0.042	-0.313	0.033
55445	0.017	-0.397	-0.012

55451	0.061	-0.319	0.002
55452	0.011	-0.375	-0.016
55453	-0.002	-0.390	-0.021
55454	-0.026	-0.471	-0.061
55455	-0.051	-0.555	-0.103
55511	0.195	0.028	0.178
55512	0.145	-0.028	0.165
55513	0.132	-0.043	0.162
55514	0.108	-0.124	0.113
55515	0.083	-0.208	0.063
55521	0.131	-0.071	0.152
55522	0.081	-0.127	0.132
55523	0.068	-0.142	0.127
55524	0.044	-0.223	0.083
55525	0.019	-0.307	0.037
55531	0.115	-0.095	0.145
55532	0.065	-0.151	0.124
55533	0.052	-0.166	0.118
55534	0.028	-0.247	0.075
55535	0.003	-0.331	0.030
55541	0.070	-0.200	0.078
55542	0.020	-0.256	0.060
55543	0.007	-0.271	0.055
55544	-0.018	-0.352	0.015
55545	-0.043	-0.436	-0.026
55551	0.001	-0.358	-0.024
55552	-0.049	-0.414	-0.037
55553	-0.062	-0.429	-0.040
55554	-0.086	-0.510	-0.074
55555	-0.111	-0.594	-0.109

11.6 Appendix 6: Lab Reference Ranges

For some lab parameters, operational site (**PPD**) confirmed that lab ranges are missing. Hence corresponding text book ranges will be used in database. Details of those ranges are as follows:

FormName	AnalyteName	LabLow	LabHigh	LabUnits	Reference
Urinalysis	Urine Specific Gravity	1.005	1.030		Laboratory and Diagnostic Tests, 8 th ED. Frances Talaska Fishbach, Marshall Barnett Dunning, Lippincott Williams & Wilkins - Wolter Kluwer, Inc. Page 201
Urinalysis	Urine pH	4.6	8.0		Laboratory and Diagnostic Tests, 8 th ED. Frances Talaska Fishbach, Marshall Barnett Dunning, Lippincott Williams & Wilkins - Wolter Kluwer, Inc. Page 202
Coagulation - Liver Abnormality Assessment	Prothrombin Time Intl. Normalized Ratio	0.93	1.13		Hematology clinical principles and applications. 3rd ED. Bernadette F Rodak; George A Fritsma; Kathryn Doig. St. Louis, Mo Saunders Elsevier 2007

Document Approval Signature(s)

This document has been signed electronically in compliance with IQVIA and IQVIA Companies' electronic signature policies and procedures. This page is a manifestation of the electronic signatures, which may be confirmed within the IQVIA and IQVIA Companies' source system in accordance with IQVIA and IQVIA Companies' records retention policies.

Note: the Title field in the signature block has been intentionally left blank.

UserName: **PPD**

Title:

Date: Tuesday, 28 January 2020, 01:56 AM Eastern Time

Meaning: I Approve the Document

=====

UserName: **PPD**

Title:

Date: Tuesday, 28 January 2020, 02:00 AM Eastern Time

Meaning: I Approve the Document

=====